<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7751407">7751407</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33327806">33327806</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1862101">10.1080/14756366.2020.1862101</a></span><span class="publisher-id" title="publisher-id">1862101</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Original Article</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3Î² inhibitors targeting breast cancer: design, synthesis, biological evaluation, and <i>in silico</i> studies</div> <div class="alt-title" title="alt-title">
W. M. Eldehna et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">Wagdy M.</span></span><a href="#AF0001">a</a><a href="#AN0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Rashood</span><span class="given-names" tagx="given-names" title="given-names">Sara T.</span></span><a href="#AF0002">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Warhi</span><span class="given-names" tagx="given-names" title="given-names">Tarfah</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eskandrani</span><span class="given-names" tagx="given-names" title="given-names">Razan O.</span></span><a href="#AF0002">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alharbi</span><span class="given-names" tagx="given-names" title="given-names">Amal</span></span><a href="#AF0002">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">Ahmed M.</span></span><a href="#AF0004">d</a><a href="#AF0005">e</a></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</span><span class="city" tagx="city" title="city">Kafr El-Sheikh</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University</span><span class="city" tagx="city" title="city">Riyadh</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University</span><span class="city" tagx="city" title="city">Riyadh</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0004">[d], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0005">[e], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Giza University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span></div> <div class="author-notes" title="author-notes"> <div class="fn-type-" title=""> <p content-type="appended text">Supplemental data for this article can be accessed <a href="https://doi.org/10.1080/14756366.2020.1862101"><u>here</u></a>.</p> </div> <div class="corresp" title="corresp"><b>CONTACT</b> Wagdy M. Eldehna <span class="email" tagx="email" title="email">wagdy2000@gmail.com</span><span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</span>, <span class="city" tagx="city" title="city">Kafr El-Sheikh</span>, <span class="postal-code" tagx="postal-code" title="postal-code">33516</span>, <span class="country" tagx="country" title="country">Egypt</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2020-12-12</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">270</span><span class="lpage" tagx="lpage" title="lpage">285</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1862101.pdf" title="self-uri">IENZ_36_1862101.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>The serine/threonine protein kinases CDK2 and GSK-3Î² are key oncotargets in breast cancer cell lines, therefore, in the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3Î² inhibitors targeting breast cancer (<b>5aâ€"g</b>, <b>7aâ€"h</b>, and <b>13aâ€"b</b>). The <i>N<sup>1</sup></i>-unsubstituted oxindole derivatives, <b>series 5</b>, showed moderate to potent activity on both MCF-7 and T-47D breast cancer cell lines. Compounds <b>5dâ€"f</b> showed the most potent cytotoxic activity with IC<sub>50</sub> of 3.41, 3.45 and 2.27â€‰Î¼M, respectively, on MCF-7 and of 3.82, 4.53 and 7.80â€‰Î¼M, respectively, on T-47D cell lines, in comparison to the used reference standard (staurosporine) IC<sub>50</sub> of 4.81 and 4.34â€‰Î¼M, respectively. On the other hand, the <i>N<sup>1</sup></i>-substituted oxindole derivatives, <b>series 7</b> and <b>13</b>, showed moderate to weak cytotoxic activity on both breast cancer cell lines. CDK2 and GSK-3Î² enzyme inhibition assay of <b>series 5</b> revealed that compounds <b>5d</b> and <b>5f</b> are showing potent dual CDK2/GSK-3Î² inhibitory activity with IC<sub>50</sub> of 37.77 and 52.75â€‰nM, respectively, on CDK2 and 32.09 and 40.13â€‰nM, respectively, on GSK-3Î². The most potent compounds <b>5dâ€"f</b> caused cell cycle arrest in the G2/M phase in MCF-7 cells inducing cell apoptosis because of the CDK2/GSK-3Î² inhibition. Molecular docking studies showed that the newly synthesised <i>N<sup>1</sup></i>-unsubstituted oxindole hybrids have comparable binding patterns in both CDK2 and GSK-3Î². The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2 and Asp133 and Val135, respectively, in GSK-3Î². Whereas, in series <b>7</b> and <b>13</b>, the <i>N<sup>1</sup></i>-substitutions on the oxindole nucleus hinder the compounds from achieving these key interactions with hinge region amino acids what rationalises their moderate to low anti-proliferative activity.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Dual kinase inhibitors</div> <div class="kwd" title="kwd">
CDK2/GSK-3Î² inhibitors</div> <div class="kwd" title="kwd">
Benzofuran-2-carbohydrazide</div> <div class="kwd" title="kwd">
Isatin</div> <div class="kwd" title="kwd">
anticancer agents</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Protein kinases (PKs) represent the fifth largest human protein family comprising 518 proteins<a href="#CIT0001"><sup>1â€"2</sup></a>. They are key regulators of cell functions through cellular signalling modulation and complex biological functions coordination such as cell growth, differentiation, proliferation, metabolism, migration, and apoptosis (programmed cell death)<a href="#CIT0001"><sup>1</sup></a><sup>,</sup><a href="#CIT0003"><sup>3â€"5</sup></a>. PKs exert their functions through catalysing the transfer of the gamma-phosphate group of an ATP molecule onto a substrate protein hydroxyl group (substrate protein phosphorylation) accomplishing cellular signals transduction and amplification<a href="#CIT0001"><sup>1</sup></a>. According to the phosphorylated residue in the substrate protein, PKs are classified into tyrosine kinases (90 kinases) and serine/threonine kinases (385 kinases), with a small group of dual specificity kinases including MEK1 and MEK2 which could catalyse the phosphorylation of both tyrosine and threonine on target proteins<a href="#CIT0006"><sup>6â€"7</sup></a>.</p> <p>The prominent and critical importance of PKs dictates strict regulation of their cellular levels and activities, therefore, PKs dysregulation contributes to several diseases such as cancer, metabolic disorders (such as diabetes), cardiovascular diseases, neurodegenerative diseases (such as Alzheimerâ€™s disease), inflammatory disorders and autoimmune diseases (such as rheumatoid arthritis)<a href="#CIT0008"><sup>8</sup></a>. The usage of PKs inhibitors is a promising strategy to manage their dysregulation in these diseases<a href="#CIT0008"><sup>8â€"11</sup></a>. In cancer treatment, PK inhibitors represent a key class of targeted chemotherapy which is devoid of the common side effects of conventional cancer chemotherapy because they target cancer cellsâ€™ signalling pathways and microenvironment with minimum undesirable effects on normal cells<a href="#CIT0012"><sup>12â€"15</sup></a>.</p> <p>Breast cancer is a very common cancer type all over the world, and despite of its possible early detection by advanced diagnostic techniques, breast cancer is still considered the leading cause of death among women worldwide<a href="#CIT0016"><sup>16â€"17</sup></a>. Thus, there is a serious continuous demand for the discovery of more effective anti-breast cancer agents. Several studies reported the overexpression of several PKs in primary as well as in metastatic breast cancers such as vascular endothelial growth factor receptor (VEGFR)<a href="#CIT0018"><sup>18â€"20</sup></a>, fibroblast growth factor receptor (FGFR)<a href="#CIT0020"><sup>20â€"21</sup></a>, platelet-derived growth factor receptor (PDGFR)<a href="#CIT0020"><sup>20</sup></a><sup>,</sup><a href="#CIT0022"><sup>22</sup></a>, cyclin dependent kinases (CDKs) and their activating cyclins<a href="#CIT0023"><sup>23â€"27</sup></a>, and glycogen synthase kinase 3Î² (GSK-3Î²)<a href="#CIT0028"><sup>28â€"30</sup></a> and references therein.</p> <p>CDKs, a family of serine/threonine protein kinases, are involved in several cellular functions such as division, proliferation, apoptosis, and gene transcription. CDK1, CDK2, CDK4 and CDK6 subtypes are responsible for the regulation of cell-cycle progression in its different phases, moreover, they play a pivotal role in cancer cell continuous proliferation<a href="#CIT0031"><sup>31â€"33</sup></a>. CDK2 subtype, specifically, received a great attention as a therapeutic target for cancer treatment due to its key role in several cellular processes upon complexation with its activating cognate, cyclin A or E, in addition, dysregulation of CDK2 or its cyclin partners was detected in various cancers such as ovarian, lung, pancreatic carcinomas, melanoma as well as breast cancer <a href="#CIT0023"><sup>23â€"27</sup></a><sup>,</sup><a href="#CIT0034"><sup>34â€"37</sup></a>. The impact of CDK2 inhibition on cancer cells confirmed the validity of CDK2 as a promising anticancer drug target, therefore, many CDK2 inhibitors have been progressed through clinical trials (<a href="#F0001">Figure 1</a>)<a href="#CIT0034"><sup>34</sup></a><sup>,</sup><a href="#CIT0035"><sup>35</sup></a><sup>,</sup><a href="#CIT0038"><sup>38</sup></a>. In particular, CDK2 inhibition was found to effectively hinder breast cancer cells proliferation including those resistant to hormonal therapy<a href="#CIT0039"><sup>39â€"41</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>CDKs inhibitors in the clinical trial phases.</p>   </div> <p>GSK-3, another serine/threonine protein kinase and an essential element of the WNT signalling pathway, contributes to several physiological processes ranging from gene expression to glycogen metabolism<a href="#CIT0042"><sup>42</sup></a>. GSK-3 has two isozymes Î± and Î² encoded by two independent GSK-3 genes<a href="#CIT0043"><sup>43â€"48</sup></a>. GSK-3Î² is known as the â€œmulti-tasking kinaseâ€� due to its participation in several signalling pathways<a href="#CIT0049"><sup>49</sup></a>. Dysregulated activity of GSK-3Î² is associated with several diseases such as type 2 diabetes, heart disease, chronic inflammatory diseases, neurodegenerative diseases, and cancer, therefore, GSK-3Î² inhibition is a potential approach for the treatment of these diseases<a href="#CIT0030"><sup>30</sup></a><sup>,</sup><a href="#CIT0050"><sup>50</sup></a>. GSK-3Î² is overexpressed in colon, pancreatic as well as breast cancers as it plays a key role in cancer cell proliferation and survival<a href="#CIT0028"><sup>28</sup></a><sup>,</sup><a href="#CIT0029"><sup>29</sup></a><sup>,</sup><a href="#CIT0051"><sup>51</sup></a>. The overexpression of GSK-3Î² correlates with poor prognosis in patients with breast cancer<a href="#CIT0028"><sup>28â€"29</sup></a>, moreover, aberrant nuclear accumulation of GSK-3Î² in five human breast cancer cell lines and in 70% of human breast carcinomas was reported<a href="#CIT0029"><sup>29</sup></a>, furthermore, GSK-3Î² inhibition suppressed the viability of breast cancer cells <i>inÂ vitro</i>, moreover, GSK-3Î² inhibition overcomes chemoresistance in human breast cancer<a href="#CIT0052"><sup>52</sup></a>.</p> <p>The complex nature of cancer mandates the implementation of multitarget treatment strategies<a href="#CIT0053"><sup>53â€"55</sup></a>. Moreover, in several cancer types especially solid tumours, such as breast cancer, more than one PK is upregulated and contributes to carcinogenesis<a href="#CIT0054"><sup>54</sup></a><sup>,</sup><a href="#CIT0056"><sup>56</sup></a>. Furthermore, drug resistance is commonly developed by target PK mutation, target PK amplification/overexpression, or through upregulation of alternative/downstream pathways<a href="#CIT0054"><sup>54</sup></a>. Thus, the use of multiple PK inhibitors is an emerging and appealing trend to overcome cancer development, progression, and resistance. A possible drawback of this approach is the pharmacokinetics (ADME) interference among the co-administered inhibitors, another concern is the potential toxicity of the used combination. To avoid these drawbacks, the design of small-molecules that are intentionally tailored to target more than one PK (multikinase inhibitors) was considered<a href="#CIT0053"><sup>53â€"55</sup></a><sup>,</sup><a href="#CIT0057"><sup>57</sup></a><sup>,</sup><a href="#CIT0058"><sup>58</sup></a>. Multikinase inhibitors with favourable selectivity or multitarget selectivity (poly-specific inhibitors) might be more suitable for cancer treatment to balance efficacy and toxicity<a href="#CIT0053"><sup>53â€"55</sup></a><sup>,</sup><a href="#CIT0057"><sup>57</sup></a><sup>,</sup><a href="#CIT0058"><sup>58</sup></a>.</p> <p>Dual CDKs/GSK-3Î² inhibition is a promising therapeutic approach to confront uncontrolled cancer cell proliferation<a href="#CIT0035"><sup>35</sup></a><sup>,</sup><a href="#CIT0036"><sup>36</sup></a><sup>,</sup><a href="#CIT0051"><sup>51</sup></a><sup>,</sup><a href="#CIT0059"><sup>59â€"66</sup></a>. In particular, CDK2 and GSK-3Î² share a high homologous sequence (33% amino acid identity) and are used as examples for the homological CMGC protein kinase family<a href="#CIT0059"><sup>59</sup></a><sup>,</sup><a href="#CIT0064"><sup>64</sup></a><sup>,</sup><a href="#CIT0067"><sup>67â€"75</sup></a>. Therefore, designing dual CDK2/GSK-3Î² inhibitors as anticancer agents is an amenable and attractive strategy<a href="#CIT0065"><sup>65â€"66</sup></a>.</p> <p>1<i>H</i>-indole-2,3-dione (isatin) is a privileged scaffold that emerged as a promising nucleus in medicinal chemistry demonstrating a broad range of pharmacological activities including antibacterial, anticonvulsant, antifungal, antiviral, as well as anticancer activity<a href="#CIT0076"><sup>76â€"78</sup></a>. Isatin derivatives exert their anticancer activity through several mechanisms such as inhibition and/or modulation of proteases, translation initiation, angiogenesis or tubulin polymerisation, moreover, PK inhibition is one of the key anticancer mechanisms of isatin derivatives<a href="#CIT0076"><sup>76â€"78</sup></a>. Several oxindole-based multikinase inhibitors (<a href="#F0002">Figure 2</a>) have been approved for cancer treatment such as sunitinib (2006) for gastrointestinal stromal tumour and renal cell carcinoma as PDGFR and VEGFR inhibitor<a href="#CIT0079"><sup>79</sup></a>, and nintedanib (2014) for idiopathic pulmonary fibrosis as FGFR, PDGFR and VEGFR inhibitor<a href="#CIT0080"><sup>80</sup></a>. Moreover, several oxindole derivatives have been designed and synthesised as inhibitors for diverse PKs such as FLT3 kinase<a href="#CIT0081"><sup>81</sup></a>, VEGFR<a href="#CIT0082"><sup>82â€"83</sup></a>, polo-like kinase 4 (PLK4)<a href="#CIT0084"><sup>84</sup></a>, aurora B kinase<a href="#CIT0085"><sup>85</sup></a>, p90 ribosomal S6 protein kinase 2 (RSK2)<a href="#CIT0086"><sup>86</sup></a>, microtubule affinity-regulating kinase 4 (MARK4)<a href="#CIT0087"><sup>87</sup></a> as well as CDKs<a href="#CIT0078"><sup>78</sup></a><sup>,</sup><a href="#CIT0088"><sup>88</sup></a>, and GSK-3Î²<a href="#CIT0059"><sup>59</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Oxindole derivatives with multikinase activity.</p>   </div> <p>The naturally occurring oxindole derivative, indirubin, (<a href="#F0002">Figure 2</a>) has been identified as the main active ingredient of the traditional Chinese medicinal remedy, <i>Dang Gui Long Hui Wan</i> which is used to treat chronic myelocytic leukaemia (CML)<a href="#CIT0064"><sup>64</sup></a><sup>,</sup><a href="#CIT0066"><sup>66</sup></a><sup>,</sup><a href="#CIT0089"><sup>89</sup></a>. Indirubin and its derivatives showed distinctive antiproliferative effect which is attributed to their inhibition of CDKs and GSK-3 through competing with ATP at the kinase domain<a href="#CIT0074"><sup>74</sup></a><sup>,</sup><a href="#CIT0090"><sup>90â€"93</sup></a>.</p> <p>Benzofuran is another privileged scaffold that demonstrated several desirable biological activities among which are analgesic, anti-inflammatory, antipyretic, antibacterial, antifungal, antiviral, antihyperglycemic, anti-hyperlipidemic, anti-oxidant, as well as anticancer activities<a href="#CIT0094"><sup>94â€"96</sup></a>. Benzofuran derivatives mediate their anticancer activity through several mechanism such as farnesyltransferase, angiogenesis, oestrogen receptor, human peptide deformylase, tubulin polymerisation, and carbonic anhydrase inhibition<a href="#CIT0094"><sup>94</sup></a><sup>,</sup><a href="#CIT0097"><sup>97</sup></a> and reference therein. Moreover, some benzofuran derivatives exert their anticancer activity through PK inhibition such as Pim-1<a href="#CIT0098"><sup>98</sup></a>, mTOR signaling<a href="#CIT0099"><sup>99â€"100</sup></a>, Src kinase<a href="#CIT0101"><sup>101</sup></a>, as well as GSK-3Î²<a href="#CIT0051"><sup>51</sup></a> (<a href="#F0003">Figure 3</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>Benzofuran derivatives with GSK-3Î² inhibitory activity.</p>   </div> <p>Based on the reported PK inhibitory activity of isatin and benzofuran nuclei, specially, on the homologous CDK2 and GSK-3Î² kinases, a hybridisation strategy of these two privileged scaffolds was adapted to design dual CDK2/GSK-3Î² hybrid inhibitors which could target breast cancer. For the hybridisation strategy, the bioisosteric amido and uriedo moieties were used as linkers between the two nuclei, moreover, different substitution pattern and nature on the oxindole ring offering various electronic and lipophilic environments were introduced to study their impact on the activity (<a href="#F0004">Figure 4</a>). On account of the hydrophobic nature of the CDK2 binding site, it was anticipated that the grafting a hydrophobic substituent (such as Br) within the benzofuran motif could achieve a plenty of hydrophobic interactions.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>Designed oxindole/benzofuran dual CDK2/GSK-3Î² hybrid inhibitors.</p>   </div> <p>The newly synthesised compounds were experimentally evaluated for their anti-proliferative activities against breast cancer cell lines T-47D and MCF-7. Compounds showed promising anti-proliferative activity were tested for their potential dual CDK2/GSK-3Î² inhibitory activity, moreover, compounds showed prominent anti-proliferative activity and <i>inÂ vitro</i> PK inhibitory activity were investigated further by studying their effect on cell cycle progression and cell apoptosis. Furthermore, molecular docking studies were also performed to study the interaction of the newly synthesised hybrid compounds with CDK2 and GSK-3Î² kinase domain hot spots (key amino acids) to rationalise their biological activity and to reveal their probable binding mode.</p> </div> <div class="resultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>The synthetic strategies designed for the preparation of the target final compounds (<b>5a-g</b>, <b>7a-h</b> and <b>13a-b</b>) were illustrated in <a href="#s0001 s0002 s0003">Schemes 1â€"3</a>. In <a href="#s0001">Scheme 1</a>, bromobenzofuran-2-carbohydrazide <b>3</b> was prepared <i>via</i> reaction of ethylbromacetate with 5-bromosalicylaldehyde <b>1</b> in acetonitrile to furnish ethyl 5-bromobenzofuran-2-carboxylate <b>2</b>. Thereafter, the ester functionality was subjected to hydrazinolysis via refluxing hydrazine hydrate to afford the key intermediate hydrazide <b>3</b>, further; this key intermediate <b>3</b> was condensed with different isatin derivatives <b>4a-g</b> in absolute ethyl alcohol with catalytic drops of glacial acetic acid to get the final novel compounds <b>5a-g</b>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthesis of target compounds <b>5aâ€"g</b>; Reagents and conditions: (<b>i</b>) Ethyl bromoacetate/Acetonitrile/K<sub>2</sub>CO<sub>3</sub>/reflux 4â€‰h, (<b>ii</b>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 3â€‰h, (<b>iii</b>) Ethanol/glacial acetic acid (Cat.)/reflux 4â€"7â€‰h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 2.</span></a></div>   <p>Synthesis of target compounds <b>7a-h</b>; Reagents and conditions: (<b>i</b>) R<sub>2</sub>-Br/anhydrous DMF/K<sub>2</sub>CO<sub>3</sub>/reflux 4â€‰h, (<b>ii</b>) Ethanol/drops glacial acetic acid (Cat.)/reflux 4â€"7â€‰h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 3.</span></a></div>   <p>Synthesis of target compounds <b>13a-b</b>; Reagents and conditions: (<b>i</b>) HCl/reflux 6â€‰h, (<b>ii</b>) (COCl)<sub>2</sub>/anhydrous toluene/reflux 5â€‰h, (<b>iii</b>) NaN<sub>3</sub>/acetone/stirring r.t. 1â€‰h, (<b>iv</b>) Dry toluene/reflux 1â€‰h. (<b>v</b>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 3â€‰h, (<b>vi</b>) Anhydrous toluene/reflux 4â€‰h.</p>   </div> <p>In <a href="#s0002">Scheme 2</a>, isatin derivatives <b>4a</b> and <b>4d</b> were subjected to <i>N</i>-alkylation in anhydrous DMF to furnish <i>N</i>-substituted isatin <b>6a-h</b>, which then condensed with the key intermediate <b>3</b> to afford target compounds <b>7a-h</b>.</p> <p>In the last scheme, the ester moiety of 5-bromobenzofuran-2-carboxylate <b>2</b> succumbed to acidic hydrolysis to afford the acid analogue <b>8</b>, which was chlorinated with oxalyl chloride in toluene to get the acid chloride derivative <b>9</b> that reacted with NaN<sub>3</sub> in acetone to produce 5-bromobenzofuran-2-carbonyl azide <b>10</b>. The azide derivative <b>10</b> was subjugated to Curtius Rearrangement through heating in anhydrous toluene to furnish isocyanate analogue <b>11</b>. On the other hand, isatin derivatives <b>6c</b> and <b>6e</b> were condensed with hydrazine hydrate to release their hydrazone analogue <b>12a</b> and <b>12â€‰b</b>, respectively, which reacted with isocyanate analogue <b>11</b> to get the final target compounds <b>13a-b</b>.</p> <p>The structures of all the synthesised compounds were confirmed under the basis of spectral and elemental analyses which were in full agreement with the proposed structures.</p> </div> <div class="biologicalevaluation" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Biological evaluation</div> <p>All the newly synthesised compounds were initially tested for their anti-proliferative activity against breast cancer cell lines T-47D and MCF-7 in MTT assay. Compounds showed promising anti-proliferative activity were tested for their PK inhibitory activity on the target kinases CDK-2 and GSK-3Î². Furthermore, compounds showed prominent activity at cellular level and on enzymes were further evaluated for their effect on cell cycle progression and cell apoptosis in the breast cancer cell line MCF-7.</p> <div class="invitroanti-proliferativeactivity" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title">
In vitro <i>anti-proliferative activity</i></div> <p>All the newly synthesised benzofuran-oxindole hybrids were screened for their <i>inÂ vitro</i> anti-proliferative activity against the breast cancer cell lines T-47D and MCF-7 using the MTT assay, and the results were compared with the pan-kinase inhibitor staurosporine as a reference standard <a href="#CIT0102"><sup>102</sup></a>. The IC<sub>50</sub> values are presented in <a href="#t0001">Table 1</a>.</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p><i>In vitro</i> anti-proliferative activity of hybrids <b>5aâ€"g</b>, <b>7aâ€"h</b> and <b>13aâ€"b</b> against breast T-47D and MCF-7 cancer cell lines.<span class="inline-graphic" title="inline-graphic" /></p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Comp.</th> <th rowspan="2" align="center">R</th> <th rowspan="2" align="center">R<sub>1</sub></th> <th rowspan="2" align="center">R<sub>2</sub></th> <th colspan="2" align="center">IC<sub>50</sub> (ÂµM)<sup>a</sup><hr /> </th> </tr> <tr> <th align="center">MCF-7</th> <th align="center">T-47D</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5a</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">5.47â€‰Â±â€‰0.16</td> <td align="char" char=".">9.67â€‰Â±â€‰0.31</td> </tr> <tr> <td align="left"><b>5b</b></td> <td align="center">F</td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">12.93â€‰Â±â€‰0.38</td> <td align="char" char=".">1.27â€‰Â±â€‰0.04</td> </tr> <tr> <td align="left"><b>5c</b></td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">12.46â€‰Â±â€‰0.37</td> <td align="char" char=".">6.03â€‰Â±â€‰0.19</td> </tr> <tr> <td align="left"><b>5d</b></td> <td align="center">Br</td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">3.41â€‰Â±â€‰0.10</td> <td align="char" char=".">3.82â€‰Â±â€‰0.12</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="center">CH<sub>3</sub></td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">3.45â€‰Â±â€‰0.10</td> <td align="char" char=".">4.53â€‰Â±â€‰0.14</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="center">OCH<sub>3</sub></td> <td align="center">H</td> <td align="center">â€"</td> <td align="char" char=".">2.27â€‰Â±â€‰0.06</td> <td align="char" char=".">7.80â€‰Â±â€‰0.25</td> </tr> <tr> <td align="left"><b>5g</b></td> <td align="center">CH<sub>3</sub></td> <td align="center">CH<sub>3</sub></td> <td align="center">â€"</td> <td align="char" char=".">11.95â€‰Â±â€‰0.35</td> <td align="char" char=".">6.65â€‰Â±â€‰0.21</td> </tr> <tr> <td align="left"><b>7a</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>3</sub></td> <td align="char" char=".">10.43â€‰Â±â€‰1.01</td> <td align="char" char=".">11.79â€‰Â±â€‰1.05</td> </tr> <tr> <td align="left"><b>7b</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>CHâ€‰=â€‰CH<sub>2</sub></td> <td align="char" char=".">2.64â€‰Â±â€‰0.07</td> <td align="char" char=".">12.24â€‰Â±â€‰0.40</td> </tr> <tr> <td align="left"><b>7c</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="char" char=".">37.04â€‰Â±â€‰1.87</td> <td align="char" char=".">43.27â€‰Â±â€‰2.39</td> </tr> <tr> <td align="left"><b>7d</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>COOC<sub>2</sub>H<sub>5</sub></td> <td align="char" char=".">7.48â€‰Â±â€‰0.22</td> <td align="char" char=".">18.99â€‰Â±â€‰0.62</td> </tr> <tr> <td align="left"><b>7e</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>Ph</td> <td align="char" char=".">8.33â€‰Â±â€‰0.24</td> <td align="char" char=".">11.80â€‰Â±â€‰0.38</td> </tr> <tr> <td align="left"><b>7f</b></td> <td align="center">H</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>CH<sub>2</sub>Ph</td> <td align="char" char=".">24.67â€‰Â±â€‰0.72</td> <td align="char" char=".">38.7â€‰Â±â€‰1.26</td> </tr> <tr> <td align="left"><b>7g</b></td> <td align="center">Br</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="char" char=".">24.82â€‰Â±â€‰0.73</td> <td align="char" char=".">9.67â€‰Â±â€‰0.31</td> </tr> <tr> <td align="left"><b>7h</b></td> <td align="center">Br</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>Ph</td> <td align="char" char=".">4.32â€‰Â±â€‰0.12</td> <td align="char" char=".">1.72â€‰Â±â€‰0.04</td> </tr> <tr> <td align="left"><b>13a</b></td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="char" char=".">18.21â€‰Â±â€‰0.53</td> <td align="char" char=".">3.22â€‰Â±â€‰0.10</td> </tr> <tr> <td align="left"><b>13b</b></td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">CH<sub>2</sub>Ph</td> <td align="char" char=".">5.70â€‰Â±â€‰0.16</td> <td align="char" char=".">10.88â€‰Â±â€‰0.35</td> </tr> <tr> <td align="left"><b>Staurosporine</b></td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="char" char=".">4.81â€‰Â±â€‰0.14</td> <td align="char" char=".">4.34â€‰Â±â€‰0.14</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>a</sup></span><p>IC<sub>50</sub> values are the meanâ€‰Â±â€‰SD of three separate experiments.</p> </div> </div> </div> <p>On MCF-7 cell line, the tested hybrids showed an IC<sub>50</sub> range of 2.27â€"37.04â€‰ÂµM, with compounds <b>5d-f</b>, <b>7â€‰b</b> and <b>7â€‰h</b> showing potent cytotoxic effect (3.41, 3.45, 2.27, 2.64 and 4.32â€‰ÂµM, respectively) compared to the reference staurosporine which showed an IC<sub>50</sub> of 4.81â€‰ÂµM. Compounds <b>5a</b>, <b>7d</b>, <b>7e</b> and <b>13â€‰b</b> showed moderate cytotoxic activity with IC<sub>50</sub> of 5.47, 7.48, 8.33 and 5.70, respectively, whereas, the rest of compounds showed weak cytotoxic activity with IC<sub>50</sub> higher than 10â€‰ÂµM (<a href="#t0001">Table 1</a>).</p> <p>On T-47D cell line, the tested compounds showed an IC<sub>50</sub> range of 1.27â€"43.27â€‰ÂµM, with compounds <b>5â€‰b</b>, <b>5d-e</b>,<b>7h</b> and <b>13a</b> showing potent cytotoxic effect (IC<sub>50</sub> of 1.27, 3.82, 4.53, 1.72 and 3.22â€‰ÂµM, respectively) compared to the reference staurosporine which showed an IC<sub>50</sub> of 4.34â€‰ÂµM. Compounds <b>5a</b>, <b>5c</b>, <b>5f</b>, <b>5â€‰g</b> and <b>7â€‰g</b> showed moderate cytotoxic activity with IC<sub>50</sub> of 9.67, 6.03, 7.80, 6.65 and 9.67â€‰ÂµM, respectively, whereas, the rest of compounds showed weak cytotoxic activity with IC<sub>50</sub> higher than 10â€‰ÂµM (<a href="#t0001">Table 1</a>).</p> <p>These results indicate the superior cytotoxic activity of the <i>N</i>-unsubstituted isatin derivatives <b>5a-g</b> on both breast cancer cell lines with IC<sub>50</sub> range of 2.27â€"12.93â€‰ÂµM and 1.27â€"9.67â€‰ÂµM on MCF-7 and T-47D cell lines, respectively, which could be due to their better binding to the target kinases. Compounds <b>5dâ€"f</b> with Br, CH<sub>3</sub> and OCH<sub>3</sub> substituent on the isatin nucleus, respectively, showed the best cytotoxic activity (<a href="#t0001">Table 1</a>).</p> <p>Series <b>7</b> showed moderate to weak cytotoxic activity on either or both cell lines, except for the <i>N</i>-benzylisatin hybrid <b>7â€‰h</b> which showed a potent cytotoxic activity on both cell lines with IC<sub>50</sub> of 4.32 and 1.72â€‰ÂµM on MCF-7 and T-47D, respectively. These results indicate that the <i>N</i>-substitution at the isatin nucleus greatly affects the cytotoxic activity in the newly synthesised compounds mostly in a negative manner (<a href="#t0001">Table 1</a>).</p> <p>Worthy of note, replacing the amido group in compound <b>7c</b> and <b>7e</b> with the ureido moiety to afford <b>13a</b> and <b>13â€‰b</b> greatly enhanced the cytotoxic activity in both cell lines (37.04 and 8.33â€‰ÂµM <i>vs</i> 18.21 and 5.70â€‰ÂµM, respectively, in MCF-7) and (43.27 and 11.80â€‰ÂµM <i>vs</i> 3.22 and 10.88â€‰ÂµM, respectively, in T-47D) (<a href="#t0001">Table 1</a>).</p> </div> <div class="cdk2andgsk-3Î²inhibitoryactivities" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
CDK2 and GSK-3Î² inhibitory activities</div> <p>The most potent hybrids on breast cancer cell lines (<b>series 5</b>) were further evaluated biochemically for their kinase inhibitory activity on CDK-2 and GSK-3Î² using their Kinase Assay Kits, and were compared to the pan-kinase inhibitor staurosporine as a reference standard. The results were presented in <a href="#t0002">Table 2</a>.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>Inhibitory activities of compounds <b>5aâ€"g</b> against CDK2 and GSK-3Î².</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Comp.</th> <th colspan="2" align="center">IC<sub>50</sub> (nM)<sup>a</sup><hr /> </th> </tr> <tr> <th align="center">CDK2</th> <th align="center">GSK-3Î²</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5a</b></td> <td align="char" char="Â±">140.6â€‰Â±â€‰7.7</td> <td align="char" char="Â±">136.9â€‰Â±â€‰7.5</td> </tr> <tr> <td align="left"><b>5b</b></td> <td align="char" char="Â±">52.46â€‰Â±â€‰2.9</td> <td align="char" char="Â±">212.3â€‰Â±â€‰12</td> </tr> <tr> <td align="left"><b>5c</b></td> <td align="char" char="Â±">85.36â€‰Â±â€‰4.6</td> <td align="char" char="Â±">102â€‰Â±â€‰5.6</td> </tr> <tr> <td align="left"><b>5d</b></td> <td align="char" char="Â±">37.77â€‰Â±â€‰2.1</td> <td align="char" char="Â±">32.09â€‰Â±â€‰1.7</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="char" char="Â±">176.5â€‰Â±â€‰9.6</td> <td align="char" char="Â±">80.75â€‰Â±â€‰4.4</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="char" char="Â±">52.75â€‰Â±â€‰2.9</td> <td align="char" char="Â±">40.13â€‰Â±â€‰2.2</td> </tr> <tr> <td align="left"><b>5g</b></td> <td align="char" char="Â±">104.8â€‰Â±â€‰5.7</td> <td align="char" char="Â±">75.54â€‰Â±â€‰4.1</td> </tr> <tr> <td align="left"><b>Staurosporine</b></td> <td align="char" char="Â±">38.5â€‰Â±â€‰2.1</td> <td align="char" char="Â±">43.38â€‰Â±â€‰2.4</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>a</sup></span><p>IC<sub>50</sub> values are the meanâ€‰Â±â€‰SD of three separate experiments.</p> </div> </div> </div> <p>On CDK2, the tested compounds showed potent sub-micromolar inhibitory activity with IC<sub>50</sub> ranged from 37.80 to 177â€‰nM in comparison to that of the used reference standard (IC<sub>50</sub> = 38.50â€‰nM). The bromo isatin derivative <b>5d</b> showed the most potent inhibitory activity with IC<sub>50</sub> of 37.80â€‰nM comparable to that of staurosporine. Compounds <b>5â€‰b</b>, <b>5c</b> and <b>5f</b> showed two-digit nanomolar inhibitory activity with IC<sub>50</sub> of 52.50, 85.40 and 52.80, respectively (<a href="#t0002">Table 2</a>).</p> <p>On GSK-3Î², the tested compounds showed potent sub-micromolar inhibitory activity as well with IC<sub>50</sub> range of 32.09â€"212.30â€‰nM in comparison to the used reference standard (IC<sub>50</sub> = 43.38â€‰nM). The bromo isatin <b>5d</b> and the methoxy isatin <b>5f</b> derivative showed more potent inhibitory activity than that of staurosporine (IC<sub>50</sub> of 32.09 and 40.13â€‰nM, respectively). Compounds <b>5e</b> and <b>5â€‰g</b> showed two-digit nanomolar inhibitory activity with IC<sub>50</sub> of 75.54 and 80.75â€‰nM, respectively (<a href="#t0002">Table 2</a>).</p> <p>These results indicate the superiority of the bromo isatin <b>5d</b> and the methoxy isatin <b>5f</b> derivatives on both kinases (<a href="#t0002">Table 2</a>). The methyl isatin derivative <b>5e</b> shows a relatively less kinase inhibitory activity than its bromo <b>5d</b> and methoxy <b>5f</b> congeners on both kinases despite of its obvious potent cellular cytotoxicity which could be attributed to its probable further cytotoxic mechanisms besides CDK2/GSK-3Î² dual inhibition.</p> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>Cyclin E/CDK2 complexation plays an important role at G1 phase, whereas, cyclin A/CDK2 complexation terminates S phase and drives the cell cycle through normal G2/M phase progression<a href="#CIT0025"><sup>25</sup></a><sup>,</sup><a href="#CIT0037"><sup>37</sup></a><sup>,</sup><a href="#CIT0103"><sup>103</sup></a><sup>,</sup><a href="#CIT0104"><sup>104</sup></a>. Furthermore, a significant percentage of CDK2-deficient cells arrest in the G2/M phase, additionally, breast cancer cells exposed to CDK2 inhibitors show G2/M phase arrest<a href="#CIT0023"><sup>23</sup></a><sup>,</sup><a href="#CIT0105"><sup>105</sup></a>. In the same vein, GSK-3Î² regulates the strength of the mitotic checkpoint and connects the PI3K and WNT-signalling pathways to mitosis, furthermore, GSK-3Î² inhibitors induce G2/M phase arrest as well<a href="#CIT0030"><sup>30</sup></a><sup>,</sup><a href="#CIT0106"><sup>106</sup></a><sup>,</sup><a href="#CIT0107"><sup>107</sup></a>.</p> <p>Compounds showing promising antiproliferative as well as kinase inhibitory activity <b>5d</b>, <b>5e</b> and <b>5f</b> were further investigated for their influence on the cell cycle progression by flow cytometry analysis using propidium iodide (PI) stain. Cell cycle parameters were compared for the breast cancer MCF-7 cells with DMSO as control and after treatment with the compounds of interest and incubation for 24â€‰h, and the results were presented in <a href="#F0005">Figure 5</a> and <a href="#t0003">Table 3</a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Effect of hybrids <b>5d</b>, <b>5e</b> and <b>5f</b> on the phases of cell cycle of MCF-7 cells.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p>Effect of compounds <b>5d</b>, <b>5e</b> and <b>5f</b> on the phases of cell cycle of MCF-7 cells</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Comp.</th> <th align="center">%G0-G1</th> <th align="center">%S</th> <th align="center">%G2/M</th> <th align="center">%Sub-G1</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5d</b></td> <td align="left">33.97</td> <td align="left">22.5</td> <td align="left">30.26</td> <td align="char" char=".">13.27</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="left">29.85</td> <td align="left">23.21</td> <td align="left">29.21</td> <td align="char" char=".">17.73</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="left">22.28</td> <td align="left">17.88</td> <td align="left">37.82</td> <td align="char" char=".">22.02</td> </tr> <tr> <td align="left"><b>Control</b></td> <td align="left">53.59</td> <td align="left">33.82</td> <td align="left">11.3</td> <td align="char" char=".">1.29</td> </tr> </tbody> </table> </div> <p>From the obtained results <a href="#F0005">Figure 5</a> and <a href="#t0003">Table 3</a>, it is noticeable that there is an increase in the percent of cell distribution in the G2/M phase, from 11.30% in control to 30.26, 29.21 and 37.82% in treated cells with <b>5d</b>, <b>5e</b> and, <b>5f</b>, respectively, indicating a G2/M phase arrest which is the expected consequence from CDK2/GSK-3Î² dual inhibition confirming the mechanism of action of the designed compounds on the target kinases. Furthermore, an increase in the percent of cells accumulated in the sub-G1 phase, from 1.29% in the control to 13.27, 17.73 and 22.02% in the treated cells with <b>5d</b>, <b>5e</b> and, <b>5f</b>, respectively, as a result of cell apoptosis.</p> <p>The high efficacy of compound <b>5f</b> in cell arrest at G2/M phase and in cell apoptosis as indicated by its results in <a href="#t0003">Table 3</a> relative to its congeners <b>5d</b> and <b>5e</b> aligns with its potent effect on MCF-7 as indicated by its IC<sub>50</sub> (2.27â€‰Î¼M) in comparison to the IC<sub>50</sub> of compounds <b>5d</b> and <b>5e</b> (3.41 and 3.45â€‰Î¼M, respectively).</p> </div> <div class="apoptosisassay" title="sec"><span class="label" tagx="label" title="label">2.2.4.</span><div class="title" tagx="title" title="title">
Apoptosis assay</div> <p>To investigate further the effect of the promising compounds <b>5d</b>, <b>5e</b>, and <b>5f</b> on cell apoptosis, Annexin V-FITC/propidium iodide dual staining assay was performed according to the reported method<a href="#CIT0108"><sup>108</sup></a>. The morphological markers of apoptosis in the breast cancer MCF-7 cell line were examined before and after treatment with the compounds of interest. Apoptosis assay depends on the translocation of the phosphatidylserine (PS) phospholipid to the cell surface in cells undergoing apoptosis which can be easily detected by staining with the fluorescent conjugate of annexin V followed by flow cytometry analysis. Simultaneously, MCF-7 cells were stained with propidium iodide (PI) which could enter cells with damaged plasma membranes only. This enables the discrimination between early apoptotic cells (positive for PS, but negative for PI) from late apoptotic and necrotic cells (positive for both PS and PI).</p> <p><a href="#F0006">Figure 6</a> and <a href="#t0004">Table 4</a> show that the percentage of the total apoptotic cells in MCF-7 cell line increases after treatment with compounds <b>5d</b>, <b>5e</b>, and <b>5f</b> (13.75, 19.74, and 26.10%, respectively) relative to control cells (0.82%) which is a significant indication of the apoptotic effect of the compounds of interest. Compounds <b>5d</b>, <b>5e</b>, and <b>5f</b> produced an increase in the early apoptotic phase, from 0.63 to 3.61, 4.66, and 3.94, respectively, and an increase in the late apoptotic phase, from 0.19 to 10.14, 15.08, and 22.16, respectively.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 6.</span></a></div>   <p>Effect of <b>5d</b>, <b>5e</b> and <b>5f</b> on the percentage of annexin V-FITC-positive staining in MCF-7 cells. The experiments were done in triplicates. The four quadrants identified as: <b>LL</b>, viable; <b>LR</b>, early apoptotic; <b>UR</b>, late apoptotic; <b>UL</b>, necrotic.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0004" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 4.</span> <p>Distribution of apoptotic cells in the AnnexinV-FITC/PI dual staining assay in MCF-7 cells upon treatment with compounds <b>5d</b>, <b>5e</b> and <b>5f</b>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Comp.</th> <th align="center">Total (L.R % + U.R %)</th> <th align="center">Early Apoptosis (Lower Right %)</th> <th align="center">Late Apoptosis (Upper Right %)</th> <th align="center">Necrosis</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5d</b></td> <td align="char" char=".">13.75</td> <td align="char" char=".">3.61</td> <td align="char" char=".">10.14</td> <td align="char" char=".">1.56</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="char" char=".">19.74</td> <td align="char" char=".">4.66</td> <td align="char" char=".">15.08</td> <td align="char" char=".">1.81</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="char" char=".">26.10</td> <td align="char" char=".">3.94</td> <td align="char" char=".">22.16</td> <td align="char" char=".">2.14</td> </tr> <tr> <td align="left"><b>Control</b></td> <td align="char" char=".">0.82</td> <td align="char" char=".">0.63</td> <td align="char" char=".">0.19</td> <td align="char" char=".">0.49</td> </tr> </tbody> </table> </div> </div> <div class="cytotoxicitytowardsnon-tumorigeniccells" title="sec"><span class="label" tagx="label" title="label">2.2.5.</span><div class="title" tagx="title" title="title">
Cytotoxicity towards non-tumorigenic cells</div> <p>In order to investigate their selectivity on cancer cells, hybrids <b>5d</b>, <b>5e</b> and <b>5f</b>, endowed with dual growth inhibitory action against MCF-7 and T-47D cells, were assesses for their cytotoxic action towards the non-tumorigenic breast cells (MCF-10A), <i>via</i> the MTT assay. The obtained IC<sub>50</sub>s and the calculated mean tumour selectivity index (S.I.); IC<sub>50</sub> for MCF-10A/IC<sub>50</sub> average for (MCF-7 and T-47D) have been presented in <a href="#t0005">Table 5</a>. The examined hybrids exerted weak cytotoxic effect (IC<sub>50</sub> = 21.66â€‰Â±â€‰1.05, 23.59â€‰Â±â€‰0.86 and 39.95â€‰Â±â€‰1.42â€‰Î¼M, respectively, with selectivity indexes equal 6.0, 5.9 and 7.9, respectively, <a href="#t0005">Table 5</a>.</p> <div class="table-wrap_UNKNOWN" id="t0005" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 5.</span> <p>Cytotoxic action for hybrids <b>5d</b>, <b>5e</b> and <b>5f</b> towards non-tumorigenic breast cell line (MCF-10A), and mean tumour selectivity index (S.I.) (MCF-10A/MCF-7 and T-47D).</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Comp.</th> <th colspan="3" align="center">IC<sub>50</sub> (ÂµM) <hr /> </th> <th rowspan="2" align="center">Mean tumour selectivity</th> </tr> <tr> <th align="center">MCF-10A</th> <th align="center">MCF-7</th> <th align="center">T-47D</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5d</b></td> <td align="left">21.66â€‰Â±â€‰1.05</td> <td align="left">3.41â€‰Â±â€‰0.10</td> <td align="left">3.82â€‰Â±â€‰0.12</td> <td align="char" char=".">6.0</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="left">23.59â€‰Â±â€‰0.86</td> <td align="left">3.45â€‰Â±â€‰0.10</td> <td align="left">4.53â€‰Â±â€‰0.14</td> <td align="char" char=".">5.9</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="left">39.95â€‰Â±â€‰1.42</td> <td align="left">2.27â€‰Â±â€‰0.06</td> <td align="left">7.80â€‰Â±â€‰0.25</td> <td align="char" char=".">7.9</td> </tr> </tbody> </table> </div> </div> </div> </div> <div class="moleculardockingstudyandstructureactivityrelationship" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Molecular docking study and structure activity relationship</div> <p>In the present molecular docking study, a pair of protein structures were used for CDK2 and GSK-3Î², <i>viz</i>, PDB ID: 1FVT<a href="#CIT0109"><sup>109</sup></a> and PDB ID: 1Q41<a href="#CIT0110"><sup>110</sup></a>, respectively, which are co-crystallized with potent CDK2 and GSK-3Î² oxindole-based inhibitors, respectively. Molecular docking was carried out to investigate the interaction of the designed hybrid compounds with CDK2 and GSK-3Î² kinase domain to rationalise their biological activity, to reveal their probable binding pattern and to elicit their SAR.</p> <p>Initially, self-docking of the co-crystallized ligands in CDK2 and GSK-3Î² active sites was performed to validate the used molecular docking protocol. The self-docking step stimulated the binding pattern of the co-crystallized ligands accurately indicating the suitability of the used docking setup for the planned simulations. This was demonstrated by the small RMSD between the docked and the co-crystallized ligand poses in CDK2 (0.894â€‰Ã…) and GSK-3Î² (0.471â€‰Ã…), and by the ability of the attained docking poses to simulate the main interactions achieved by the co-crystallized ligands with the key amino acids in CDK2 and GSK-3Î² active sites (<a href="#F0007">Figures 7</a> and <a href="#CIT0008">8</a>, respectively).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 7.</span></a></div>   <p>(<b>A</b>) 2â€‰D interaction diagram showing the oxindole derivative docking pose interactions with the key amino acids (hot spots) in the CDK2 active site. (Distances in Ã…) (<b>B</b>) 3â€‰D representations of the superimposition of the docking pose (green) and the co-crystallized pose (red) of the oxindole derivative in the CDK2 active site, respectively, with RMSD of 0.894â€‰Ã….</p>   </div> <p>In the CDK2 active site the docking pose of the oxindole derivative reproduced the key interactions of the co-crystalized ligand with the active site; it interacts in the hinge region through hydrogen bonding with Glu81 backbone CO and Leu83 backbone NH and CO. Furthermore, its sulfonamidophenylhydrazone group projected outward towards the bulk solvent with the sulphonamide group interacting with Asp86 backbone NH and side-chain carboxyl group and Lys89 side chain NH<sub>3</sub><sup>+</sup> (<a href="#F0007">Figure 7</a>).</p> <p>As for GSK-3Î², the docking pose of indirubin-3â€²-monoxime reproduced the key interactions of the co-crystalized ligand with the active site; it interacts in the hinge region through hydrogen bonding with Asp133 backbone CO and Val135 backbone NH and CO (<a href="#F0008">Figure 8</a>). Furthermore, through a water mediated hydrogen bonding network, it interacts with Gln185 and Thr138 by its oxime group which is responsible for its selectivity towards GSK-3Î² over CDK2.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 8.</span></a></div>   <p>(<b>A</b>) 2â€‰D interaction diagram showing Indirubin-3'-monoxime docking pose interactions with the key amino acids (hot spots) in the GSK-3Î² active site. (Distances in Ã…) (<b>B</b>) 3â€‰D representations of the superimposition of the docking pose (green) and the co-crystallized pose (red) of Indirubin-3'-monoxime in the GSK-3Î² active site, respectively, with RMSD of 0.471â€‰Ã….</p>   </div> <p>In series <b>5</b>, the newly synthesised <i>N<sup>1</sup></i>-unsubstituted oxindole hybrids showed comparable binding patterns in both kinases (<a href="#F0009">Figures 9</a> and <a href="#F0010">10</a> and for further details, see supporting materials). The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding by its NH and CO with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2, and Asp133 and Val135, respectively, in GSK-3Î².</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 9.</span></a></div>   <p>2â€‰D diagram (<b>A</b>) and 3â€‰D representation (<b>B</b>) of compound <b>5f</b> showing its interaction with the CDK2 active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 10.</span></a></div>   <p>2â€‰D diagram (<b>A</b>) and 3â€‰D representation (<b>B</b>) of compound <b>5f</b> showing its interaction with the GSK-3Î² active site.</p>   </div> <p>Moreover, through hydrophobic interaction the fused phenyl ring of the oxindole nucleus interacts with the hydrophobic side chains of the surrounding amino acids; Val18, Ala31, Val64, Phe80, Leu134, and Ala144 in CDK2 and Val70, Ala83, Val110, Leu132, Leu188, and Cys199 in GSK-3Î² (<a href="#F0009">Figures 9</a> and <a href="#F0010">10</a> and for further details, see supporting materials). Therefore, increasing the substituent hydrophobicity on the oxindole nucleus enhances the binding affinity which is well reflected in the docking binding score and further in the biological activity (Br, <b>5d</b> &amp;gt; Cl, <b>5c</b> â‰ˆ CH<sub>3</sub>, <b>5e</b> &amp;gt; F, <b>5â€‰b</b>) (<a href="#t0001 t0002 t0006">Tables 1, 2 and 6</a>). The remarkable binding affinity of the relatively polar methoxy group (OCH<sub>3</sub>, <b>5f</b>) is attributed to the fact that it is directed towards the bulk solvent and so decreased the solvation penalty during the binding scenario resulting in a considerable increase in the binding affinity. On the other hand, despite of its relatively higher hydrophobicity, the dimethyl substituted hybrid <b>5â€‰g</b> does not show significant predicted binding score or experimental biological activity what could be attributed to the C<sup>7</sup> methyl substituent which sterically clashes with the bottom of the hinge region hindering the key interaction of the NH and CO of the oxindole ring with the key amino acids; Glu81 and Leu83 in CDK2, respectively, and Asp133 and Val135 in GSK-3Î², respectively (For further details, see supporting materials).</p> <div class="table-wrap_UNKNOWN" id="t0006" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 6.</span> <p>Docking energy scores (<i>S</i>) in kcal/mol for the newly synthesised hybrid compounds and the co-crystalized compounds in CDK2 and GSK-3Î² kinase domain</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compound</th> <th align="center">Energy score (S) kcal/mol CDK2</th> <th align="center">Energy score (S) kcal/mol GSK-3Î²</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left">5a</td> <td align="char" char=".">âˆ’9.53</td> <td align="char" char=".">âˆ’9.99</td> </tr> <tr> <td align="left">5b</td> <td align="char" char=".">âˆ’9.89</td> <td align="char" char=".">âˆ’10.40</td> </tr> <tr> <td align="left">5c</td> <td align="char" char=".">âˆ’10.07</td> <td align="char" char=".">âˆ’10.59</td> </tr> <tr> <td align="left">5d</td> <td align="char" char=".">âˆ’10.22</td> <td align="char" char=".">âˆ’10.81</td> </tr> <tr> <td align="left">5e</td> <td align="char" char=".">âˆ’10.05</td> <td align="char" char=".">âˆ’10.53</td> </tr> <tr> <td align="left">5f</td> <td align="char" char=".">âˆ’10.35</td> <td align="char" char=".">âˆ’10.96</td> </tr> <tr> <td align="left">5g</td> <td align="char" char=".">âˆ’10.39</td> <td align="char" char=".">âˆ’10.60</td> </tr> <tr> <td align="left">7a</td> <td align="char" char=".">âˆ’9.19</td> <td align="char" char=".">âˆ’10.40</td> </tr> <tr> <td align="left">7b</td> <td align="char" char=".">âˆ’9.61</td> <td align="char" char=".">âˆ’10.24</td> </tr> <tr> <td align="left">7c</td> <td align="char" char=".">âˆ’10.03</td> <td align="char" char=".">âˆ’11.48</td> </tr> <tr> <td align="left">7d</td> <td align="char" char=".">âˆ’10.21</td> <td align="char" char=".">âˆ’11.76</td> </tr> <tr> <td align="left">7e</td> <td align="char" char=".">âˆ’9.98</td> <td align="char" char=".">âˆ’11.58</td> </tr> <tr> <td align="left">7f</td> <td align="char" char=".">âˆ’10.05</td> <td align="char" char=".">âˆ’10.68</td> </tr> <tr> <td align="left">7g</td> <td align="char" char=".">âˆ’10.56</td> <td align="char" char=".">âˆ’11.27</td> </tr> <tr> <td align="left">7h</td> <td align="char" char=".">âˆ’10.40</td> <td align="char" char=".">âˆ’11.46</td> </tr> <tr> <td align="left">13a</td> <td align="char" char=".">âˆ’13.60</td> <td align="char" char=".">âˆ’11.77</td> </tr> <tr> <td align="left">13b</td> <td align="char" char=".">âˆ’14.72</td> <td align="char" char=".">âˆ’11.92</td> </tr> <tr> <td align="left">Co-crystalized ligand</td> <td align="char" char=".">âˆ’10.63</td> <td align="char" char=".">âˆ’12.00</td> </tr> </tbody> </table> </div> <p>The hydrazono linker NH interacts through hydrogen bonding with the backbone CO of Leu83 and Val135 in CDK2 and GSK-3Î², respectively, projecting the benzofuran moiety outward towards the bulk solvent which is involved in a hydrophobic interaction with the hydrophobic side chains of the surrounding amino acids lining the gate of the hinge region; Ile10, Phe82, and Leu298 in CDK2 and Ile62, Tyr134 and Pro136 in GSK-3Î² (<a href="#F0009">Figures 9</a> and <a href="#F0010">10</a> and for further details, see supporting materials).</p> <p>In series <b>7</b> and <b>13</b>, the <i>N<sup>1</sup></i>-substitutions on the oxindole nucleus hinder the compounds from achieving the key interactions with hinge region amino acids; Glu81 and Leu83 in CDK2, and Asp133 and Val135 in GSK-3Î² what rationalises their moderate to low antiproliferative activity (For further details, see supporting materials). Molecular docking simulations show their non-selective bindings and random binding patterns what rationalise their low activity despite of their good docking binding scores (<a href="#t0006">Table 6</a>).</p> <p>These results point out the criticality of N<sup>1</sup> being unsubstituted for CDK2/GSK-3Î² kinase inhibition. The N<sup>1</sup>-benzyloxindole derivative <b>7â€‰h</b> showing promising antiproliferative activity might be exerting its effect through other mechanism than CDK2/GSK-3Î² kinase inhibition.</p> </div> <div class="conclusions" title="sec"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusions</div> <p>In the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3Î² inhibitors targeting breast cancer (<b>5a-g</b>, <b>7a-h</b>, and <b>13a-b</b>). In MTT assay on the breast cancer cell lines MCF-7 and T-47D, the <i>N<sup>1</sup></i>-unsubstituted oxindole derivatives, <b>series 5</b>, showed moderate to potent activity on both breast cancer cell lines. Compounds <b>5d-f</b> showed the most potent cytotoxic activity with IC<sub>50</sub> of 3.41, 3.45 and 2.27â€‰Î¼M, respectively, on MCF-7 and IC<sub>50</sub> of 3.82, 4.53 and 7.80â€‰Î¼M, respectively, on T-47D cell lines, in comparison to the used reference standard (staurosporine) IC<sub>50</sub> of 4.81 and 4.34â€‰Î¼M, respectively. On the other hand, the <i>N<sup>1</sup></i>-substituted oxindole derivatives, <b>series 7 and 13</b>, showed moderate to weak cytotoxic activity on both breast cancer cell lines except for compound <b>7â€‰h</b> which showed potent antiproliferative activity with IC<sub>50</sub> of 4.32 and 1.72â€‰Î¼M on MCF-7 and T-47D cell lines, respectively. CDK2 and GSK-3Î² inhibition testing of the potent <b>series 5</b> indicated that compounds <b>5d</b> and <b>5f</b> exhibit potent dual CDK2/GSK-3Î² inhibitory activity with IC<sub>50</sub> of 37.77 and 52.75â€‰nM, respectively, on CDK2 and 32.09 and 40.13â€‰nM, respectively, on GSK-3Î². The most potent hybrids <b>5d-f</b> triggered cell cycle arrest in the G2/M phase as a consequence of their dual CDK2/GSK-3Î² inhibition. Moreover, compounds <b>5d-f</b> induced apoptosis in MCF-7 cells as indicated by the percent of the total apoptosis of 13.75, 19.74, and 26.10%, respectively, in comparison to the untreated cells which showed 0.82% total apoptosis. The molecular docking study showed that the newly synthesised <i>N<sup>1</sup></i>-unsubstituted oxindole hybrids have comparable binding patterns in both CDK2 and GSK-3Î². The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2 and Asp133 and Val135, respectively, in GSK-3Î². Moreover, through hydrophobic interaction the fused phenyl ring of the oxindole nucleus interacts with the hydrophobic side chains of the surrounding amino acids; Val18, Ala31, Val64, Phe80, Leu134, and Ala144 in CDK2 and Val70, Ala83, Val110, Leu132, Leu188, and Cys199 in GSK-3Î². The hydrazono linker NH interacts through hydrogen bonding with the backbone CO of Leu83 and Val135 in CDK2 and GSK-3Î², respectively, projecting the benzofuran moiety outward towards the bulk solvent which is involved in a hydrophobic interaction with the hydrophobic side chains of the surrounding amino acids lining the gate of the hinge region; Ile10, Phe82, and Leu298 in CDK2 and Ile62, Tyr134 and Pro136 in GSK-3Î². In series <b>7</b> and <b>13</b>, the <i>N<sup>1</sup></i>-substitutions on the oxindole nucleus hinder the compounds from achieving the key interactions with hinge region amino acids; Glu81 and Leu83 in CDK2, and Asp133 and Val135 in GSK-3Î² what rationalises their moderate to low antiproliferative activity.</p> </div> <div class="experimental" title="sec"><span class="label" tagx="label" title="label">5.</span><div class="title" tagx="title" title="title">
Experimental</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">5.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <div class="general" title="sec"><span class="label" tagx="label" title="label">5.1.1.</span><div class="title" tagx="title" title="title">
General</div> <p>Melting points were measured with a Stuart melting point apparatus and were uncorrected. Infra-red spectra were recorded on Schimadzu FT-IR 8400S spectrophotometer. The NMR spectra were recorded by Bruker spectrometer at 400â€‰MHz. <sup>13â€‰</sup>C NMR spectra were run at 100â€‰MHz in deuterated dimethylsulphoxide (DMSO<i>d6</i>). Elemental analyses were carried out at the Regional Centre for Microbiology and Biotechnology, Al-Azhar University, Cairo, Egypt. Unless otherwise noted, all solvents and reagents were commercially available and used without further purification. Compounds (<b>2</b> and <b>3</b>)<a href="#CIT0097"><sup>97</sup></a>, (<b>6aâ€"h</b>)<a href="#CIT0111"><sup>111â€"112</sup></a>, (<b>8â€"9</b>)<a href="#CIT0113"><sup>113</sup></a>, and (<b>12â€‰b</b>)<a href="#CIT0114"><sup>114</sup></a> were prepared according to the reported methods.</p> <div class="synthesisof5-bromobenzofuran-2-carbohydrazide3" title="sec"><span class="label" tagx="label" title="label">5.1.1.2.</span><div class="title" tagx="title" title="title">
Synthesis of 5-bromobenzofuran-2-carbohydrazide 3</div> <p>To hot stirred solution of ethyl 5-bromobenzofuran-2-carboxylate <b>2</b> (1â€‰g, 3.7â€‰mmol) in 30â€‰ml of methanol, hydrazine hydrate (0.25â€‰ml, 7.5â€‰mmol) was added. The reaction solution was left for heating under reflux for 4â€‰h, and then poured onto cold water. The formed solid was collected by filtration, washed with diethyl ether and recrystallized from EtOH/DMF mixture to furnish the key intermediate <b>3</b>.</p> </div> <div class="synthesisoftargetcompounds5aâ€" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.</span><div class="title" tagx="title" title="title">
Synthesis of target compounds 5aâ€"g and 7aâ€"h</div> <p>5-Bromobenzofuran-2-carbohydrazide <b>3</b> (0.3â€‰g, 1.2â€‰mmol) was added to a hot solution of equivalent amount of the appropriate isatin derivative (<b>4aâ€"g</b> or <b>6aâ€"h</b>) in ethanol (15â€‰ml) with catalytic amount of ethanoic acid. The reaction mixture was heated under reflux for 4â€"7â€‰h with TLC monitoring, once the reaction completed, the reaction mixture was left for cooling then was filtered-off. The produced solid was washed with water, diethyl ether and recrystallized from dioxane/propanol mixture to produce target compounds <b>5aâ€"g</b> and <b>7aâ€"h</b>, respectively.</p> <div class="5-bromo-n'-(2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5a" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.1.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5a</div> <p>Yellow powder (yield 75%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 6.94â€"7.00 (m, 1H, Ar-H), 7.11 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.41â€"7.47 (m, 1H, Ar-H), 7.64â€"7.84 (m, 3H, Ar-H), 7.99 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 8.09, 8.11 (2â€‰s, 1H, Ar-H), 10.91, 11.39 (2â€‰s, 1H, NH indolin-2-one), 11.89, 14.06 (2â€‰s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 111.32, 114.73, 116.72, 120.10, 121.76, 122.45, 123.30, 126.13, 127.23, 129.61, 131.18, 132.70, 133.70, 143.29, 153.87, 163.35 (Câ€‰=â€‰O indolin-2-one), 165.04 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3380, 3345 (2NH) and 1711, 1701 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 384 [M<sup>+</sup>+2, 50.94], 382 [M<sup>+</sup>, 48.60], 160 [100]; Analysis calculated for C<sub>17</sub>H<sub>10</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 53.15; H, 2.62; N, 10.94; found C, 53.33; H, 2.64; N, 10.82.</p> </div> <div class="5-bromo-n'-(5-fluoro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5b" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.2.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-fluoro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5b</div> <p>Red powder (yield 77%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 6.92â€"7.00 (m, 1H, Ar-H), 7.24â€"7.33 (m, 1H, Ar-H), 7.49, 7.86 (2br s, 1H, Ar-H), 7.67â€"7.71 (m, 1H, Ar-H), 7.74 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.96 (d, 0.6H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 8.04â€"8.13 (m, 1.4H, Ar-H), 10.92,11.42 (2â€‰s, 1H, NH indolin-2-one), 12.02, 14.02 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3280, 3245 (2NH) and 1723, 1705 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>BrFN<sub>3</sub>O<sub>3</sub>: C, 50.77; H, 2.26; N, 10.45; found C, 50.90; H, 2.24; N, 10.57.</p> </div> <div class="5-bromo-n'-(5-chloro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5c" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.3.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-chloro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5c</div> <p>Orange powder (yield 83%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 6.94â€"7.01 (m, 1H, Ar-H), 7.45â€"7.50 (m, 1H, Ar-H), 7.64â€"7.76 (m, 2.3H, Ar-H), 8.04, 8.10 (2â€‰s, 1H, Ar-H), 8.14â€"8.17 (m, 1.7H, Ar-H), 11.03,11.50 (2â€‰s, 1H, NH indolin-2-one), 12.08, 13.96 (2â€‰s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 112.66, 114.60, 116.94, 118.92, 121.28, 124.34, 126.29, 126.77, 131.04, 132.93, 137.31, 141.43, 143.41, 153.82, 163.17 (Câ€‰=â€‰O indolin-2-one), 164.88 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3300, 3240 (2NH) and 1735, 1702 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>BrClN<sub>3</sub>O<sub>3</sub>: C, 48.77; H, 2.17; N, 10.04; found C, 48.82; H, 2.16; N, 9.93.</p> </div> <div class="5-bromo-n'-(5-bromo-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5d" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.4.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-bromo-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5d</div> <p>Orange powder (yield 87%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 6.91â€"6.97 (m, 1H, Ar-H), 7.60 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.71â€"7.76 (m, 2H, Ar-H), 8.03â€"8.15 (m, 2H, Ar-H), 8.31 (s, 1H, Ar-H), 11.05,11.52 (2â€‰s, 1H, NH indolin-2-one), 12.09, 13.99 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3295, 3271 (2NH) and 1732, 1701 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>: C, 44.09; H, 1.96; N, 9.07; found C, 43.81; H, 1.98; N, 9.16.</p> </div> <div class="5-bromo-n'-(5-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5e" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.5.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5e</div> <p>Brown powder (yield 84%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 2.23, 2.35 (2â€‰s, 3H, CH<sub>3</sub>), 6.84â€"6.88 (m, 1H, Ar-H), 7.22â€"7.27 (m, 1H, Ar-H), 7.47 (s, 0.6H, Ar-H), 7.68â€"7.71 (m, 1H, Ar-H), 7.74â€"7.79 (m, 1H, Ar-H), 7.82â€"7.88 (m, 1H, Ar-H), 8.00 (s, 0.4H, Ar-H), 8.09â€"8.14 (m, 1H, Ar-H), 10.80, 11.28 (2â€‰s, 1H, NH indolin-2-one), 11.83, 14.05 (2â€‰s, 1H, NH) ; <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 20.97 (CH<sub>3</sub>), 111.57, 114.65, 116.89, 120.09, 122.08, 126.14, 127.54, 129.60, 130.92, 131.15, 132.44, 133.12, 141.02, 142.44, 153.84, 163.41 (Câ€‰=â€‰O indolin-2-one), 165.09 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3320, 3341 (2NH) and 1721, 1700 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 54.29; H, 3.04; N, 10.55; found C, 54.57; H, 3.01; N, 10.62.</p> </div> <div class="5-bromo-n'-(5-methoxy-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5f" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.6.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-methoxy-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5f</div> <p>Red powder (yield 82%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 3.80, 3.83 (2â€‰s, 3H, OCH<sub>3</sub>), 6.85â€"6.91 (m, 1H, Ar-H), 6.98â€"7.07 (m, 1H, Ar-H), 7.18 (s, 1H, Ar-H), 7.68â€"7.76 (m, 2H, Ar-H), 7.82, 8.01 (2â€‰s, 1H, Ar-H), 8.08â€"8.13 (m, 1H, Ar-H), 10.72,11.20 (2â€‰s, 1H, NH indolin-2-one), 11.97, 14.10 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3324, 3301 (2NH) and 1718, 1710 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 416 [M<sup>+</sup>+2, 75.42], 414 [M<sup>+</sup>, 77.51], 402 [100]; Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>4</sub>: C, 52.19; H, 2.92; N, 10.14; found C, 52.01; H, 2.95; N, 10.25.</p> </div> <div class="5-bromo-n'-(5,7-dimethyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide5â€‰g" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.7.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5,7-dimethyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5â€‰g</div> <p>Red powder (yield 76%), m.p. &amp;gt; 300â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 2.20, 20.22 (2â€‰s, 3H, CH<sub>3</sub> of C-7 of indolin-2-one), 2.29, 2.32 (2â€‰s, 3H, CH<sub>3</sub> of C-5 of indolin-2-one), 7.06, 7.11 (2â€‰s, 1H, Ar-H), 7.30 (s, 0.5H, Ar-H), 7.69â€"7.71 (m, 1.5H, Ar-H), 7.75â€"7.79 (m, 1H, Ar-H), 7.82, 8.00 (2â€‰s, 1H, Ar-H), 8.09, 8.11 (2â€‰s, 1H, Ar-H), 10.82,11.29 (2â€‰s, 1H, NH indolin-2-one), 11.78, 14.06 (2â€‰s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 16.31 (CH<sub>3</sub> C-7 of indolin-2-one), 20.88 (CH<sub>3</sub> C-5 of indolin-2-one), 114.67, 116.88, 119.47, 120.97, 123.31, 126.13, 129.61, 131.11, 132.34, 134.53, 135.97, 139.65, 141.47, 142.47, 153.84, 163.82 (Câ€‰=â€‰O indolin-2-one), 165.16 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3350, 3315 (2NH) and 1723, 1701 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 414 [M<sup>+</sup>+2, 17.45], 412 [M<sup>+</sup>, 14.19], 160 [100]; Analysis calculated for C<sub>19</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 55.36; H, 3.42; N, 10.19; found C, 55.53; H, 3.38; N, 10.27.</p> </div> <div class="5-bromo-n'-(1-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide7a" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.8.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(1-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7a</div> <p>Yellow powder (yield 81%), m.p. 260â€"262â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 3.27 (s, 3H, <i>N</i>-CH<sub>3</sub>), 7.19 (t, 2H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.50 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.68â€"7.71 (m, 2H, Ar-H), 7.76 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.97, 14.02 (2â€‰s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 26.26 (<i>N</i>-CH<sub>3</sub>), 110.59, 114.68, 116.94, 119.40, 121.41, 123.84, 126.16, 129.60, 130.33, 131.24, 132.62, 138.18, 144.51, 151.44, 153.87, 161.58 (Câ€‰=â€‰O indolin-2-one), 165.10 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3345 (NH) and 1720, 1695 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 400 [M<sup>+</sup>+2, 92.41], 398 [M<sup>+</sup>, 94.85], 91 [100]; Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 54.29; H, 3.04; N, 10.55; found C, 54.48; H, 3.02; N, 10.64.</p> </div> <div class="n'-(1-allyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide7â€‰b" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.9.</span><div class="title" tagx="title" title="title">
N'-(1-Allyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7â€‰b</div> <p>Orange powder (yield 73%), m.p. 207â€"209â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 4.46 (s, 2H, <i>N</i>-CH<sub>2</sub>), 5.22â€"5.31 (m, 2H, =CH<sub>2</sub>), 5.88â€"5.97 (m, 1H, <i>N</i>-CH<sub>2</sub>-C<u>H</u>), 7.13 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.19 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.47 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.68â€"7.72 (m, 2H, Ar-H), 7.76 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz),) , 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.99, 13.97 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3304 (NH) and 1715, 1701 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>20</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 56.62; H, 3.33; N, 9.90; found C, 56.77; H, 3.31; N, 10.01.</p> </div> <div class="5-bromo-n'-(1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide7c" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.10.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7c</div> <p>Yellow powder (yield 65%), m.p. 216â€"218â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 0.94 (d, 6H, -CH-(C<u>H<sub>3</sub></u>)<sub>2</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 2.09â€"2.16 (m, 1H, <i>N</i>-CH<sub>2</sub>-C<u>H</u>), 3.36 (d, 2H, <i>N</i>-CH<sub>2</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.17 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.24 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.47 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.67â€"7.70 (m, 2H, Ar-H), 7.77 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.84 (s, 1H, Ar-H), 8.08 (s, 1H, Ar-H), 13.99 (s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3312 (NH) and 1720, 1711 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>21</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 57.29; H, 4.12; N, 9.54; found C, 57.08; H, 4.17; N, 9.47.</p> </div> <div class="ethyl-2â€" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.11.</span><div class="title" tagx="title" title="title">
Ethyl-2â€"(3-(2â€"(5-bromobenzofuran-2-carbonyl)hydrazono)-2-oxoindolin-1-yl)acetate 7d</div> <p>Orange powder (yield 69%), m.p. 215â€"216â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 1.23 (t, 3H, CH<sub>3</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 4.18 (q, 2H, CH<sub>2</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 4.76 (s, 2H, <i>N</i>-CH<sub>2</sub>), 7.22 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.50 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.96â€"7.78 (m, 2H, Ar-H), 7.87 (s, 1H, Ar-H), 8.10 (s, 1H, Ar-H), 13.81 (s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 14.49 (CH<sub>3</sub>), 41.47 (-<u>C</u>H<sub>2</sub>-CH<sub>3</sub>), 61.97 (<i>N</i>-CH<sub>2</sub>), 110.93, 113.40, 114.68, 116.96, 119.28, 121.62, 124.20, 124.67, 126.19, 129.59, 131.33, 132.68, 143.48, 150.87, 153.88, 161.55 (Câ€‰=â€‰O indolin-2-one), 165.22 (Câ€‰=â€‰O hydrazide), 167.89 (Câ€‰=â€‰O ester); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3324 (NH) and 1745, 1715, 1698 (3â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>21</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>5</sub>: C, 53.63; H, 3.43; N, 8.94; found C, 53.80; H, 3.42; N, 8.88.</p> </div> <div class="n'-(1-benzyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide7e" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.12.</span><div class="title" tagx="title" title="title">
N'-(1-Benzyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7e</div> <p>Yellow powder (yield 80%), m.p. 248â€"250â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 5.01, 5.05 (2â€‰s, 2H, <i>N</i>-CH<sub>2</sub>), 7.06 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.17 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.29â€" 7.32 (m, 4H, Ar-H), 7.42â€"7.48 (m, 2H, Ar-H), 7.69â€"7.73 (m, 1.5H, Ar-H), 7.77 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.87, 8.02 (2â€‰s, 1H, Ar-H), 8.09â€"8.12 (m, 1.5H, Ar-H), 12.01, 13.99 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3309 (NH) and 1712, 1701 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 476 [M<sup>+</sup>+2, 16.41], 474 [M<sup>+</sup>, 21.15], 475 [100]; Analysis calculated for C<sub>24</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 60.77; H, 3.40; N, 8.86; found C, 60.98; H, 3.38; N, 8.75.</p> </div> <div class="5-bromo-n'-(2-oxo-1-phenethylindolin-3-ylidene)benzofuran-2-carbohydrazide7f" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.13.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(2-oxo-1-phenethylindolin-3-ylidene)benzofuran-2-carbohydrazide 7f</div> <p>Yellow powder (yield 78%), m.p. 239â€"241â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 2.99 (br s, 2H, <i>N</i>-CH<sub>2</sub>-C<u>H<sub>2</sub></u>), 4.03 (br s, 2H, <i>N</i>-C<u>H<sub>2</sub></u>-CH<sub>2</sub>), 7.16â€"7.22 (m, 3H, Ar-H), 7.28â€"7.32 (m, 4H, Ar-H), 7.45 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.46 (t, 2H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.78 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.97, 13.94 (2â€‰s, 1H, NH); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 33.43 (<i>N</i>-CH<sub>2</sub>-<u>C</u>H<sub>2</sub>), 41.36 (<i>N</i>-<u>C</u>H<sub>2</sub>-CH<sub>2</sub>), 110.86, 114.71, 116.95, 119.34, 120.21, 121.53, 123.75, 126.15, 127.02, 127.92, 128.93, 129.34, 129.59, 130.55, 131.24, 132.58, 135.38, 138.58, 141.28, 143.61, 153.87, 161.36 (Câ€‰=â€‰O indolin-2-one), 165.06 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3356 (NH) and 1721, 1703 (2â€‰Câ€‰=â€‰O); Analysis calculated for C25H18BrN3O3: C, 61.49; H, 3.72; N, 8.60; found C, 61.63; H, 3.70; N, 8.66.</p> </div> <div class="5-bromo-n'-(5-bromo-1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide7â€‰g" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.14.</span><div class="title" tagx="title" title="title">
5-Bromo-N'-(5-bromo-1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7â€‰g</div> <p>Orange powder (yield 74%), m.p. 244â€"246â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 0.94 (d, 6H, â€"CHâ€"(C<u>H<sub>3</sub></u>)<sub>2</sub>, <i>J</i>â€‰=â€‰7.6â€‰Hz), 2.11â€"2.17 (m, 1H, <i>N</i>-CH<sub>2</sub>-C<u>H</u>), 3.51 (d, 2H, <i>N</i>-CH<sub>2</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 6.94â€"7.12 (m, 1H, Ar-H), 7.70 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.73â€"7.80 (m, 2H, Ar-H), 8.10â€"8.18 (m, 2H, Ar-H), 8.35 (s, 1H, Ar-H), 12.12, 13.98 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3358 (NH) and 1724, 1700 (2â€‰Câ€‰=â€‰O); Analysis calculated for C21H17Br2N3O3: C, 48.58; H, 3.30; N, 8.09; found C, 48.73; H, 3.27; N, 8.14.</p> </div> <div class="n'-(1-benzyl-5-bromo-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide7â€‰h" title="sec"><span class="label" tagx="label" title="label">5.1.1.3.15.</span><div class="title" tagx="title" title="title">
N'-(1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7â€‰h</div> <p>Yellow powder (yield 81%), m.p. 236â€"237â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 5.00, 5.04 (2â€‰s, 2H, <i>N</i>-C<u>H<sub>2</sub></u>), 7.03 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.29â€"7.32 (m, 1H, Ar-H), 7.35â€"7.39 (m, 2H, Ar-H), 7.42 (d, 2H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.51â€"7.61 (m, 1H, Ar-H), 7.66â€"7.70 (m, 1H, Ar-H), 7.73â€"7.77 (m, 2H, Ar-H), 7.87, 8.13 (2â€‰s, 1H, Ar-H), 8.07 (s, 1H, Ar-H), 12.19, 13.87 (2â€‰s, 1H, NH); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3335 (NH) and 1731, 1708 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>24</sub>H<sub>15</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>: C, 52.11; H, 2.73; N, 7.60; found C, 51.86; H, 2.74; N, 7.69.</p> </div> </div> <div class="synthesisof5-bromo-2-isocyanatobenzofuran11" title="sec"><span class="label" tagx="label" title="label">5.1.1.4.</span><div class="title" tagx="title" title="title">
Synthesis of 5-bromo-2-isocyanatobenzofuran 11</div> <p>5-Bromobenzofuran-2-carbonyl chloride <b>9</b> (1â€‰g, 3.8â€‰mmol) was dissolved in dry acetone (30â€‰ml), then added drop wisely to aqueous solution of equivalent amount of NaN<sub>3</sub> at 0â€‰Â°C over 30â€‰min. The formed precipitate was filtrated under vacuum and washed with pet. ether, then heated without purification in dry toluene for 1â€‰h to produce the intermediate <b>11</b>.</p> </div> <div class="synthesisofhydrazones12a-b" title="sec"><span class="label" tagx="label" title="label">5.1.1.5.</span><div class="title" tagx="title" title="title">
Synthesis of hydrazones 12a-b</div> <p>To hot stirred solution of the appropriate indolin-2-one <b>6c</b> and <b>6e</b> (6â€‰mmol) in isopropyl alcohol (22â€‰ml), hydrazine hydrate (0.50â€‰ml, 15â€‰mmol) was added. The reaction solution was heated under reflux for 3â€‰h, then cold to room temperature. The formed solid was collected <i>via</i> filtration, washed with <i>n</i>-hexane and recrystallized from acetonitrile to afford the key intermediates hydrazones <b>12a-b</b> in a good yield (87â€"92%).</p> <div class="3-hydrazono-1-isobutylindolin-2-one12a" title="sec"><span class="label" tagx="label" title="label">5.1.1.5.1.</span><div class="title" tagx="title" title="title">
3-Hydrazono-1-isobutylindolin-2-one 12a</div> <p>Yellow powder (yield 65%), m.p. 91â€"93â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 0.98 (d, 6H, -CH-(C<u>H<sub>3</sub></u>)<sub>2</sub>, <i>J</i>â€‰=â€‰6.8â€‰Hz), 2.02â€"2.12 (m, 1H, <i>N</i>-CH<sub>2</sub>-C<u>H</u>), 3.55 (d, 2H, <i>N</i>-CH<sub>2</sub>, <i>J</i>â€‰=â€‰7.6â€‰Hz), 7.02 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰7.6â€‰Hz), 7.08 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.21 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.41 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰7.6â€‰Hz), 9.67 (d, 1H, NH<sub>2</sub>, D<sub>2</sub>O exchangeable, <i>J</i>â€‰=â€‰14.8â€‰Hz), 10.54 (d, 1H, NH<sub>2</sub>, D<sub>2</sub>O exchangeable, <i>J</i>â€‰=â€‰14.8â€‰Hz); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 20.45 (â€"CHâ€"(<u>C</u>H<sub>3</sub>)<sub>2</sub>), 27.39 (<i>Nâ€"</i>CH<sub>2</sub>â€"<u>C</u>H), 46.40 (<i>Nâ€"</i>CH<sub>2</sub>), 109.59, 117.73, 121.83, 122.23, 125.66, 127.45, 140.07, 161.49 (Câ€‰=â€‰O indolin-2-one); Analysis calculated for C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O: C, 66.34; H, 6.96; N, 19.34; found C, 66.53; H, 6.91; N, 19.39.</p> </div> </div> <div class="synthesisoftargetcompounds13a-b" title="sec"><span class="label" tagx="label" title="label">5.1.1.6.</span><div class="title" tagx="title" title="title">
Synthesis of target compounds 13a-b</div> <p>To the previously prepared solution of isocyanate <b>11</b>, equimolar amount of hydrazone <b>12aâ€"b</b> was added. The reaction mixture was heated for 4â€‰h, the formed precipitate was filtrated while hot, washed with diethyl ether and recrystallized from DMF/EtOH mixture to produce targeted compounds <b>13aâ€"b</b>, respectively.</p> <div class="n-(5-bromobenzofuran-2-yl)-2â€" title="sec"><span class="label" tagx="label" title="label">5.1.1.6.1.</span><div class="title" tagx="title" title="title">
N-(5-Bromobenzofuran-2-yl)-2â€"(1-isobutyl-2-oxoindolin-3-ylidene)hydrazine-1-carboxamide 13a</div> <p>Yellow powder (yield 73%), m.p. 208â€"210â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 0.94 (d, 6H, â€"CHâ€"(C<u>H<sub>3</sub></u>)<sub>2</sub>, <i>J</i>â€‰=â€‰8.0â€‰Hz), 2.06â€"2.13 (m, 1H, <i>N</i><b>â€"</b>CH<sub>2</sub><b>â€"</b>C<u>H</u>), 3.57 (d, 2H, <i>N</i>-CH<sub>2</sub>, <i>J</i>â€‰=â€‰7.6â€‰Hz), 6.55 (s, 1H, Ar-H), 6.63 (s, 0.5H, Ar-H), 7.15â€"7.21 (m, 1H, Ar-H), 7.28â€"7.32 (m, 1.5H, Ar-H), 7.41â€"7.47 (m, 2H, Ar-H), 7.70â€"7.74 (m, 2H, Ar-H), 10.12 (s, 1H, NH urea), 11.33 (s, 1H, NH urea); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 20.44 (â€"CHâ€"(<u>C</u>H<sub>3</sub>)<sub>2</sub>), 27.28 (<i>Nâ€"</i>CH<sub>2</sub>â€"<u>C</u>H), 66.82 (<i>N</i>â€"CH<sub>2</sub>), 110.60, 112.52, 116.02, 119.90, 121.04, 122.52, 123.30, 125.07, 131.39, 132.27, 133.49, 143.34, 148.57, 148.99, 150.31, 151.01, 161.27 (Câ€‰=â€‰O indolin-2-one), 165.09 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3345, 3240 (2NH) and 1730, 1711 (2â€‰Câ€‰=â€‰O); MS <i>m/z</i> [%]: 457 [M<sup>+</sup>+2, 27.45], 455 [M<sup>+</sup>, 29.72], 414 [100]; Analysis calculated for C<sub>21</sub>H<sub>19</sub>BrN<sub>4</sub>O<sub>3</sub>: C, 55.40; H, 4.21; N, 12.31; found C, 55.59; H, 4.16; N, 12.42.</p> </div> <div class="2â€" title="sec"><span class="label" tagx="label" title="label">5.1.1.6.2.</span><div class="title" tagx="title" title="title">
2â€"(1-Benzyl-2-oxoindolin-3-ylidene)-N-(5-bromobenzofuran-2-yl)hydrazine-1-carboxamide 13â€‰b</div> <p>Yellow powder (yield 68%), m.p. 217â€"219â€‰Â°C; <sup>1</sup>H NMR <i>ppm</i>: 4.98 (s, 2H, <i>N</i>-CH<sub>2</sub>), 6.53 (s, 1H, Ar-H), 6.61 (s, 1H, Ar-H), 7.02 (d, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.11 (t, 1H, Ar-H, <i>J</i>â€‰=â€‰8.0â€‰Hz), 7.25â€"7.30 (m, 2H, Ar-H), 7.31â€"7.38 (m, 3H, Ar-H), 7.41â€"7.45 (m, 2H, Ar-H), 7.68â€"7.71 (m, 2H, Ar-H), 10.10 (s, 1H, NH urea), 11.38 (s, 1H, NH urea); <sup>13â€‰</sup>C NMR <i>Î´ ppm</i>: 42.51 (CH<sub>2</sub>), 115.57, 119.67, 120.62, 122.17, 123.04, 124.56, 124.73, 127.43, 127.63, 128.74, 130.81, 131.68, 132.92, 135.84, 142.18, 148.06, 148.21, 148.48, 149.75, 150.56, 150.69, 160.57 (Câ€‰=â€‰O indolin-2-one), 165.06 (Câ€‰=â€‰O hydrazide); IR (KBr, <i>Î½</i> cm<sup>âˆ’1</sup>) 3334, 3270 (2NH) and 1728, 1707 (2â€‰Câ€‰=â€‰O); Analysis calculated for C<sub>24</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>3</sub>: C, 58.91; H, 3.50; N, 11.45; found C, 59.22; H, 3.53; N, 11.52.</p> </div> </div> </div> </div> <div class="biologicalevaluations" title="sec"><span class="label" tagx="label" title="label">5.2.</span><div class="title" tagx="title" title="title">
Biological evaluations</div> <p>All experimental procedures utilised in the biological assays herein conducted were performed as reported earlier; anti-proliferation<a href="#CIT0115"><sup>115</sup></a>, cell cycle<a href="#CIT0116"><sup>116â€"117</sup></a>, Annexin V-FITC Apoptosis<a href="#CIT0118"><sup>118</sup></a> and CDK2 kinase<a href="#CIT0119"><sup>119</sup></a> assays, and have been provided in the <a href="https://doi.org/10.1080/14756366.2020.1862101">Supplementary Materials</a>.</p> </div> <div class="moleculardockingstudy" title="sec"><span class="label" tagx="label" title="label">5.3.</span><div class="title" tagx="title" title="title">
Molecular docking study</div> <p>All the molecular modelling simulations were performed using Molecular Operating Environment (MOE, 2010.10) software. All minimizations were carried out with MOE until an RMSD gradient of 0.05â€‰kcalÂ·mol<sup>âˆ’1â€‰</sup>Ã…<sup>âˆ’1</sup> with MMFF94Ã— force field and the partial charges were automatically calculated. The X-ray crystallographic structure of CDK2 co-crystallized with an oxindole derivative (IC<sub>50</sub> = 60â€‰nM) as inhibitor (PDB ID: 1FVT)<a href="#CIT0109"><sup>109</sup></a> and of GSK-3Î² co-crystallized with the oxindole derivative Indirubin-3â€²-monoxime (IC<sub>50</sub> = 22â€‰nM) as inhibitor (PDB ID: 1Q41)<a href="#CIT0110"><sup>110</sup></a> were downloaded from the protein data bank<a href="#CIT0120"><sup>120</sup></a>. The selection of these two protein structures specifically attributed to their co-crystallization with potent CDK2 and GSK-3Î² oxindole-based inhibitors, respectively.</p> <p>For the CDK2 protein structure (PDB ID: 1FVT); water molecules were first removed, as for the GSK-3Î² protein structure (PDB ID: 1Q41); Chain B and water molecules which are not involved in binding were first removed, whereas, two conservative water molecules near chain A Thr138 that serve a functional role in the co-crystalized inhibitor binding were kept<a href="#CIT0110"><sup>110</sup></a>. Then, the proteins were prepared for the docking study using <i>LigX</i> protocol in MOE with default options. The co-crystalized ligands were used to define the active site for docking. Triangle Matcher placement method and London dG scoring function were used for docking. Self-docking of the co-crystallized ligands in the active site of the kinase domains was first performed to validate the used docking protocol giving a docking pose with an energy score (S) = âˆ’10.63â€‰kcal/mol and an RMSD of 0.894â€‰Ã… in CDK2 (PDB ID: 1FVT) and energy score (S) = âˆ’12.00â€‰kcal/mol and an RMSD of 0.471â€‰Ã… in GSK-3Î² (PDB ID: 1Q41), <a href="#F0007">Figure 7</a> and <a href="#t0005">Table 5</a>.</p> <p>The validated docking protocols were then used to study the ligand-protein interactions of the newly synthesised compounds in the active site of the target kinases to predict their binding mode and establish their structure activity relationship (SAR) to rationalise their binding affinity.</p> </div> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supplementary Material</div> <div class="local-data" title="local-data">  <div class="title" tagx="title" title="title">
Supplemental Material</div>  <div class="media" title="media"><a href="IENZ_A_1862101_SM8866.pdf">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>No potential conflict of interest was reported by the author(s).</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Manning</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Whyte</span><span class="given-names" tagx="given-names" title="given-names">DB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martinez</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The protein kinase complement of the human genome</span>. <span class="source" tagx="source" title="source">Science</span><span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">298</span>:<span class="fpage" tagx="fpage" title="fpage">1912</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12471243">12471243</a></span></span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parang</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span></span><span class="chapter-title" tagx="chapter-title" title="chapter-title">Protein kinase inhibitors drug discovery</span> In: <span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gad</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span></span>, ed. <span class="source" tagx="source" title="source">Drug discovery handbook</span>. Hoboken, New Jersey: <span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley &amp;amp; Sons, Inc</span>; <span class="year" tagx="year" title="year">2005</span>:<span class="fpage" tagx="fpage" title="fpage">1191</span>â€"<span class="lpage" tagx="lpage" title="lpage">1257</span>.</span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roskoski</span><span class="given-names" tagx="given-names" title="given-names">R.</span><span class="suffix" tagx="suffix" title="suffix">Jr.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span>. <span class="source" tagx="source" title="source">Pharmacol Res</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">103</span>:<span class="fpage" tagx="fpage" title="fpage">26</span>â€"<span class="lpage" tagx="lpage" title="lpage">48</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26529477">26529477</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Allam</span><span class="given-names" tagx="given-names" title="given-names">HA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aly</span><span class="given-names" tagx="given-names" title="given-names">EE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Farouk</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">98</span>:<span class="fpage" tagx="fpage" title="fpage">103726</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32171987">32171987</a></span></span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Sanea</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elkamhawy</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paik</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: synthesis, biological evaluation and in silico insights</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">115525</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32371117">32371117</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alonso</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sasin</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bottini</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Protein tyrosine phosphatases in the human genome</span>. <span class="source" tagx="source" title="source">Cell</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">117</span>:<span class="fpage" tagx="fpage" title="fpage">699</span>â€"<span class="lpage" tagx="lpage" title="lpage">711</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15186772">15186772</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bononi</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Agnoletto</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">De Marchi</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Protein kinases and phosphatases in the control of cell fate</span>. <span class="source" tagx="source" title="source">Enzyme Res</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">2011</span>:<span class="fpage" tagx="fpage" title="fpage">329098</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21904669">21904669</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">PL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gray</span><span class="given-names" tagx="given-names" title="given-names">NS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Targeting cancer with small molecule kinase inhibitors</span>. <span class="source" tagx="source" title="source">Nat Rev Cancer</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">28</span>â€"<span class="lpage" tagx="lpage" title="lpage">39</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19104514">19104514</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fabbro</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruetz</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buchdunger</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Protein kinases as targets for anticancer agents: from inhibitors to useful drugs</span>. <span class="source" tagx="source" title="source">Pharmacol Ther</span><span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">93</span>:<span class="fpage" tagx="fpage" title="fpage">79</span>â€"<span class="lpage" tagx="lpage" title="lpage">98</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12191602">12191602</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pearson</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GarcÃ­a-EcheverrÃ­a</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fabbro</span><span class="given-names" tagx="given-names" title="given-names">D</span></span></span>, <span class="chapter-title" tagx="chapter-title" title="chapter-title">Protein tyrosine kinases as targets for cancer and other indications</span> In: <span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fabbro</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mc Cormick</span><span class="given-names" tagx="given-names" title="given-names">F</span></span></span>, eds. <span class="source" tagx="source" title="source">Protein tyrosine kinases - from inhibitors to useful drugs</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Totowa (NJ)</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">Humana Press Inc</span>; <span class="year" tagx="year" title="year">2006</span>:<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">29</span>.</span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sedlacek</span><span class="given-names" tagx="given-names" title="given-names">HH.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Kinase inhibitors in cancer therapy: a look ahead</span>. <span class="source" tagx="source" title="source">Drugs</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">435</span>â€"<span class="lpage" tagx="lpage" title="lpage">76</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10776829">10776829</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weinstein</span><span class="given-names" tagx="given-names" title="given-names">IB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Joe</span><span class="given-names" tagx="given-names" title="given-names">AK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy</span>. <span class="source" tagx="source" title="source">Nat Clin Pract Oncol</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">448</span>â€"<span class="lpage" tagx="lpage" title="lpage">57</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16894390">16894390</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Padma</span><span class="given-names" tagx="given-names" title="given-names">VV.</span></span></span><span class="mixed-article-title" title="mixed-article-title">An overview of targeted cancer therapy</span>. <span class="source" tagx="source" title="source">BioMedicine</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">19</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26613930">26613930</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aggarwal</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Targeted cancer therapies</span>. <span class="source" tagx="source" title="source">Nat Rev Drug Discov</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">427</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20514063">20514063</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Topcul</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cetin</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Endpoint of cancer treatment: targeted therapies</span>. <span class="source" tagx="source" title="source">Asian Pac J Cancer Prev</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">4395</span>â€"<span class="lpage" tagx="lpage" title="lpage">403</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24969859">24969859</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bray</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ferlay</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soerjomataram</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <span class="source" tagx="source" title="source">CA Cancer J Clin</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">68</span>:<span class="fpage" tagx="fpage" title="fpage">394</span>â€"<span class="lpage" tagx="lpage" title="lpage">424</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30207593">30207593</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: American Cancer Society</span></span> Cancer Facts &amp;amp; Figures <span class="year" tagx="year" title="year">2019</span> Available from: <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf">https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf</a>.</span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yan</span><span class="given-names" tagx="given-names" title="given-names">JD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">ZY</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Expression and prognostic significance of VEGFR-2 in breast cancer</span>. <span class="source" tagx="source" title="source">Pathol Res Pract</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">211</span>:<span class="fpage" tagx="fpage" title="fpage">539</span>â€"<span class="lpage" tagx="lpage" title="lpage">43</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25976977">25976977</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Colbert</span><span class="given-names" tagx="given-names" title="given-names">LS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fuller</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Vascular endothelial growth factor receptor-2 in breast cancer</span>. <span class="source" tagx="source" title="source">Biochim Biophys Acta</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">1806</span>:<span class="fpage" tagx="fpage" title="fpage">108</span>â€"<span class="lpage" tagx="lpage" title="lpage">21</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20462514">20462514</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Mohsen</span><span class="given-names" tagx="given-names" title="given-names">HT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abd El-Meguid</span><span class="given-names" tagx="given-names" title="given-names">EA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer</span>. <span class="source" tagx="source" title="source">Arch Pharm (Weinheim)</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">353</span>:<span class="fpage" tagx="fpage" title="fpage">e1900340</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32045054">32045054</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elbauomy Elsheikh</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Green</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lambros</span><span class="given-names" tagx="given-names" title="given-names">MBK</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis</span>. <span class="source" tagx="source" title="source">Breast Cancer Research</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">R23</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17397528">17397528</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vrekoussis</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stathopoulos</span><span class="given-names" tagx="given-names" title="given-names">EN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kafousi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta</span>. <span class="source" tagx="source" title="source">Oncol Rep</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">1115</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17390053">17390053</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">He</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xiang</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zong</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity inÂ vivo and inÂ vitro</span>. <span class="source" tagx="source" title="source">Cancer Cell Int</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">130</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25550687">25550687</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alexander</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karakas</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer</span>. <span class="source" tagx="source" title="source">Oncotarget</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">14897</span>â€"<span class="lpage" tagx="lpage" title="lpage">911</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28107181">28107181</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ding</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer</span>. <span class="source" tagx="source" title="source">Int J Mol Sci</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">1960</span>.</span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Harwell</span><span class="given-names" tagx="given-names" title="given-names">RM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Porter</span><span class="given-names" tagx="given-names" title="given-names">DC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Danes</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keyomarsi</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Processing of cyclin E differs between normal and tumor breast cells</span>. <span class="source" tagx="source" title="source">Cancer Res</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">60</span>:<span class="fpage" tagx="fpage" title="fpage">481</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10667604">10667604</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cooley</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zelivianski</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jeruss</span><span class="given-names" tagx="given-names" title="given-names">JS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines</span>. <span class="source" tagx="source" title="source">Cell Cycle</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">4900</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21150326">21150326</a></span></span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Quintayo</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Munro</span><span class="given-names" tagx="given-names" title="given-names">AF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thomas</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">GSK3Î² and cyclin D1 expression predicts outcome in early breast cancer patients</span>. <span class="source" tagx="source" title="source">Breast Cancer Res Treat</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">136</span>:<span class="fpage" tagx="fpage" title="fpage">161</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22976805">22976805</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Walz</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ugolkov</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chandra</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Molecular pathways: revisiting glycogen synthase Kinase-3Î² as a target for the treatment of cancer</span>. <span class="source" tagx="source" title="source">Clin Cancer Res</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">1891</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28053024">28053024</a></span></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Duda</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Akula</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abrams</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Targeting GSK3 and associated signaling pathways involved in cancer</span>. <span class="source" tagx="source" title="source">Cells</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">1110</span>.</span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malumbres</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Physiological relevance of cell cycle kinases</span>. <span class="source" tagx="source" title="source">Physiol Rev</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">91</span>:<span class="fpage" tagx="fpage" title="fpage">973</span>â€"<span class="lpage" tagx="lpage" title="lpage">1007</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21742793">21742793</a></span></span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malumbres</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Barbacid</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Mammalian cyclin-dependent kinases</span>. <span class="source" tagx="source" title="source">Trends Biochem Sci</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">30</span>: <span class="fpage" tagx="fpage" title="fpage">630</span>â€"<span class="lpage" tagx="lpage" title="lpage">41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16236519">16236519</a></span></span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lapenna</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giordano</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cell cycle kinases as therapeutic targets for cancer</span>. <span class="source" tagx="source" title="source">Nat Rev Drug Discov</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">547</span>â€"<span class="lpage" tagx="lpage" title="lpage">66</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19568282">19568282</a></span></span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Luk</span><span class="given-names" tagx="given-names" title="given-names">KC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Simcox</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schutt</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new series of potent oxindole inhibitors of CDK2</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">913</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15012993">15012993</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chohan</span><span class="given-names" tagx="given-names" title="given-names">TA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qayyum</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rehman</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers</span>. <span class="source" tagx="source" title="source">Biomed Pharmacother</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">107</span>:<span class="fpage" tagx="fpage" title="fpage">1326</span>â€"<span class="lpage" tagx="lpage" title="lpage">41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30257348">30257348</a></span></span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chohan</span><span class="given-names" tagx="given-names" title="given-names">TA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qian</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pan</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">JZ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents</span>. <span class="source" tagx="source" title="source">Curr Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">237</span>â€"<span class="lpage" tagx="lpage" title="lpage">63</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25386824">25386824</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abd El-Karim</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Syam</span><span class="given-names" tagx="given-names" title="given-names">YM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelghany</span><span class="given-names" tagx="given-names" title="given-names">TM.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: synthesis, CDK2 inhibition, QSAR and molecular docking studies</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">86</span>:<span class="fpage" tagx="fpage" title="fpage">80</span>â€"<span class="lpage" tagx="lpage" title="lpage">96</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30685646">30685646</a></span></span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Horiuchi</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huskey</span><span class="given-names" tagx="given-names" title="given-names">NE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kusdra</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways</span>. <span class="source" tagx="source" title="source">Proc Natl Acad Sci U S A</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">109</span>: <span class="fpage" tagx="fpage" title="fpage">E1019</span>â€"<span class="lpage" tagx="lpage" title="lpage">27</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22474407">22474407</a></span></span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ali</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heathcote</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kroll</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity</span>. <span class="source" tagx="source" title="source">Cancer Res</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">69</span>:<span class="fpage" tagx="fpage" title="fpage">6208</span>â€"<span class="lpage" tagx="lpage" title="lpage">15</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19638587">19638587</a></span></span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">WÄ™sierska-GÄ…dek</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gritsch</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zulehner</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-Î± in human ER-positive breast cancer cells</span>. <span class="source" tagx="source" title="source">J Cell Biochem</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">112</span>:<span class="fpage" tagx="fpage" title="fpage">761</span>â€"<span class="lpage" tagx="lpage" title="lpage">72</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21328450">21328450</a></span></span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Johnson</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bentley</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">LZ</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells</span>. <span class="source" tagx="source" title="source">Br J Cancer</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">102</span>:<span class="fpage" tagx="fpage" title="fpage">342</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20010939">20010939</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Welsh</span><span class="given-names" tagx="given-names" title="given-names">GI</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Proud</span><span class="given-names" tagx="given-names" title="given-names">CG.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B</span>. <span class="source" tagx="source" title="source">Biochem J</span><span class="year" tagx="year" title="year">1993</span>;<span class="volume" tagx="volume" title="volume">294</span>:<span class="fpage" tagx="fpage" title="fpage">625</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8397507">8397507</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Frame</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cohen</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biondi</span><span class="given-names" tagx="given-names" title="given-names">RM.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</span>. <span class="source" tagx="source" title="source">Mol Cell</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">1321</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11430833">11430833</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hooper</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Killick</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lovestone</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The GSK3 hypothesis of Alzheimerâ€™s disease</span>. <span class="source" tagx="source" title="source">J Neurochem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">104</span>:<span class="fpage" tagx="fpage" title="fpage">1433</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18088381">18088381</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bhat</span><span class="given-names" tagx="given-names" title="given-names">RV</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Budd Haeberlein</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Avila</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Glycogen synthase kinase 3: a drug target for CNS therapies</span>. <span class="source" tagx="source" title="source">J Neurochem</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">89</span>:<span class="fpage" tagx="fpage" title="fpage">1313</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15189333">15189333</a></span></span></li> <li tag="ref"><a name="CIT0046" /><span class="label" tagx="label" title="label">46</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hughes</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nikolakaki</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Plyte</span><span class="given-names" tagx="given-names" title="given-names">SE</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation</span>. <span class="source" tagx="source" title="source">Embo J</span><span class="year" tagx="year" title="year">1993</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">803</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8382613">8382613</a></span></span></li> <li tag="ref"><a name="CIT0047" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martinez</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Castro</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dorronsoro</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alonso</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation</span>. <span class="source" tagx="source" title="source">Med Res Rev</span><span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">373</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12111750">12111750</a></span></span></li> <li tag="ref"><a name="CIT0048" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Avila</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leon-Espinosa</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Garcia</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Tau phosphorylation by GSK3 in different conditions</span>. <span class="source" tagx="source" title="source">Int J Alzheimers Dis</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">2012</span>:<span class="fpage" tagx="fpage" title="fpage">578373</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22675648">22675648</a></span></span></li> <li tag="ref"><a name="CIT0049" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Doble</span><span class="given-names" tagx="given-names" title="given-names">BW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Woodgett</span><span class="given-names" tagx="given-names" title="given-names">JR.</span></span></span><span class="mixed-article-title" title="mixed-article-title">GSK-3: tricks of the trade for a multi-tasking kinase</span>. <span class="source" tagx="source" title="source">J Cell Sci</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">116</span>:<span class="fpage" tagx="fpage" title="fpage">1175</span>â€"<span class="lpage" tagx="lpage" title="lpage">86</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12615961">12615961</a></span></span></li> <li tag="ref"><a name="CIT0050" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Osman</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zaater</span><span class="given-names" tagx="given-names" title="given-names">MA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3Î² inhibitors</span>. <span class="source" tagx="source" title="source">J Mol Model</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">171</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31129879">31129879</a></span></span></li> <li tag="ref"><a name="CIT0051" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gaisina</span><span class="given-names" tagx="given-names" title="given-names">IN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gallier</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ougolkov</span><span class="given-names" tagx="given-names" title="given-names">AV</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">52</span>:<span class="fpage" tagx="fpage" title="fpage">1853</span>â€"<span class="lpage" tagx="lpage" title="lpage">63</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19338355">19338355</a></span></span></li> <li tag="ref"><a name="CIT0052" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ugolkov</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gaisina</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">JS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">GSK-3 inhibition overcomes chemoresistance in human breast cancer</span>. <span class="source" tagx="source" title="source">Cancer Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">380</span>:<span class="fpage" tagx="fpage" title="fpage">384</span>â€"<span class="lpage" tagx="lpage" title="lpage">92</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27424289">27424289</a></span></span></li> <li tag="ref"><a name="CIT0053" /><span class="label" tagx="label" title="label">53</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Branca</span><span class="given-names" tagx="given-names" title="given-names">MA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-kinase inhibitors create buzz at ASCO</span>. <span class="source" tagx="source" title="source">Nat Biotechnol</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">639</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15940222">15940222</a></span></span></li> <li tag="ref"><a name="CIT0054" /><span class="label" tagx="label" title="label">54</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Broekman</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giovannetti</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peters</span><span class="given-names" tagx="given-names" title="given-names">GJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tyrosine kinase inhibitors: multi-targeted or single-targeted?</span><span class="source" tagx="source" title="source">World J Clin Oncol</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">2</span>:<span class="fpage" tagx="fpage" title="fpage">80</span>â€"<span class="lpage" tagx="lpage" title="lpage">93</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21603317">21603317</a></span></span></li> <li tag="ref"><a name="CIT0055" /><span class="label" tagx="label" title="label">55</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Krug</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hilgeroth</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Recent advances in the development of multi-kinase inhibitors</span>. <span class="source" tagx="source" title="source">Mini Rev Med Chem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">1312</span>â€"<span class="lpage" tagx="lpage" title="lpage">27</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18991750">18991750</a></span></span></li> <li tag="ref"><a name="CIT0056" /><span class="label" tagx="label" title="label">56</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Muller-Tidow</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Diederichs</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bulk</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer</span>. <span class="source" tagx="source" title="source">Cancer Res</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">65</span>:<span class="fpage" tagx="fpage" title="fpage">1778</span>â€"<span class="lpage" tagx="lpage" title="lpage">82</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15753374">15753374</a></span></span></li> <li tag="ref"><a name="CIT0057" /><span class="label" tagx="label" title="label">57</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Garuti</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roberti</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bottegoni</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-kinase inhibitors</span>. <span class="source" tagx="source" title="source">Curr Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">695</span>â€"<span class="lpage" tagx="lpage" title="lpage">712</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25511779">25511779</a></span></span></li> <li tag="ref"><a name="CIT0058" /><span class="label" tagx="label" title="label">58</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Mohsen</span><span class="given-names" tagx="given-names" title="given-names">HT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Omar</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>; <span class="volume" tagx="volume" title="volume">179</span>:<span class="fpage" tagx="fpage" title="fpage">707</span>â€"<span class="lpage" tagx="lpage" title="lpage">22</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31284081">31284081</a></span></span></li> <li tag="ref"><a name="CIT0059" /><span class="label" tagx="label" title="label">59</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lozinskaya</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Babkov</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zaryanova</span><span class="given-names" tagx="given-names" title="given-names">EV</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3Î² inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">27</span>:<span class="fpage" tagx="fpage" title="fpage">1804</span>â€"<span class="lpage" tagx="lpage" title="lpage">17</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30902399">30902399</a></span></span></li> <li tag="ref"><a name="CIT0060" /><span class="label" tagx="label" title="label">60</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ouach</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boulahjar</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vala</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">115</span>:<span class="fpage" tagx="fpage" title="fpage">311</span>â€"<span class="lpage" tagx="lpage" title="lpage">25</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27019296">27019296</a></span></span></li> <li tag="ref"><a name="CIT0061" /><span class="label" tagx="label" title="label">61</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3Î² inhibitors: a critical review</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">164</span>:<span class="fpage" tagx="fpage" title="fpage">448</span>â€"<span class="lpage" tagx="lpage" title="lpage">70</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30616053">30616053</a></span></span></li> <li tag="ref"><a name="CIT0062" /><span class="label" tagx="label" title="label">62</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boulahjar</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ouach</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bourg</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">101</span>:<span class="fpage" tagx="fpage" title="fpage">274</span>â€"<span class="lpage" tagx="lpage" title="lpage">87</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26142492">26142492</a></span></span></li> <li tag="ref"><a name="CIT0063" /><span class="label" tagx="label" title="label">63</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boulahjar</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ouach</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Matteo</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">55</span>:<span class="fpage" tagx="fpage" title="fpage">9589</span>â€"<span class="lpage" tagx="lpage" title="lpage">606</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23083119">23083119</a></span></span></li> <li tag="ref"><a name="CIT0064" /><span class="label" tagx="label" title="label">64</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Polychronopoulos</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Magiatis</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Skaltsounis</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">47</span>:<span class="fpage" tagx="fpage" title="fpage">935</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14761195">14761195</a></span></span></li> <li tag="ref"><a name="CIT0065" /><span class="label" tagx="label" title="label">65</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mettey</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gompel</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thomas</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">46</span>:<span class="fpage" tagx="fpage" title="fpage">222</span>â€"<span class="lpage" tagx="lpage" title="lpage">36</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12519061">12519061</a></span></span></li> <li tag="ref"><a name="CIT0066" /><span class="label" tagx="label" title="label">66</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3Î² (GSK-3Î²) phosphorylation inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">86</span>:<span class="fpage" tagx="fpage" title="fpage">165</span>â€"<span class="lpage" tagx="lpage" title="lpage">74</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25151579">25151579</a></span></span></li> <li tag="ref"><a name="CIT0067" /><span class="label" tagx="label" title="label">67</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Patel</span><span class="given-names" tagx="given-names" title="given-names">DS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dessalew</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Iqbal</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bharatam</span><span class="given-names" tagx="given-names" title="given-names">PV.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Structure-based approaches in the design of GSK-3 selective inhibitors</span>. <span class="source" tagx="source" title="source">Curr Protein Pept Sci</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">352</span>â€"<span class="lpage" tagx="lpage" title="lpage">64</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17696868">17696868</a></span></span></li> <li tag="ref"><a name="CIT0068" /><span class="label" tagx="label" title="label">68</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arfeen</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Patel</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bharatam</span><span class="given-names" tagx="given-names" title="given-names">PV.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Molecular dynamics simulation studies of GSK-3Î² ATP competitive inhibitors: understanding the factors contributing to selectivity</span>. <span class="source" tagx="source" title="source">J Biomol Struct Dyn</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">33</span>:<span class="fpage" tagx="fpage" title="fpage">2578</span>â€"<span class="lpage" tagx="lpage" title="lpage">93</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26209183">26209183</a></span></span></li> <li tag="ref"><a name="CIT0069" /><span class="label" tagx="label" title="label">69</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Echalier</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Endicott</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Noble</span><span class="given-names" tagx="given-names" title="given-names">ME.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Recent developments in cyclin-dependent kinase biochemical and structural studies</span>. <span class="source" tagx="source" title="source">Biochim Biophys Acta</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">1804</span>:<span class="fpage" tagx="fpage" title="fpage">511</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19822225">19822225</a></span></span></li> <li tag="ref"><a name="CIT0070" /><span class="label" tagx="label" title="label">70</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Davies</span><span class="given-names" tagx="given-names" title="given-names">TG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tunnah</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meijer</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate</span>. <span class="source" tagx="source" title="source">Structure</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">389</span>â€"<span class="lpage" tagx="lpage" title="lpage">97</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11377199">11377199</a></span></span></li> <li tag="ref"><a name="CIT0071" /><span class="label" tagx="label" title="label">71</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Czelen</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Inhibition mechanism of CDK-2 and GSK-3beta by a sulfamoylphenyl derivative of indoline-a molecular dynamics study</span>. <span class="source" tagx="source" title="source">J Mol Model</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">230</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28726150">28726150</a></span></span></li> <li tag="ref"><a name="CIT0072" /><span class="label" tagx="label" title="label">72</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pacureanu</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Avram</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bora</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Portraying the selectivity of GSK-3 inhibitors towards CDK-2 by 3D similarity and molecular docking</span>. <span class="source" tagx="source" title="source">Struct Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">30</span>:<span class="fpage" tagx="fpage" title="fpage">911</span>â€"<span class="lpage" tagx="lpage" title="lpage">23</span>.</span></li> <li tag="ref"><a name="CIT0073" /><span class="label" tagx="label" title="label">73</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ko</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">EY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chiu</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A hierarchical phosphorylation cascade that regulates the timing of PERIOD nuclear entry reveals novel roles for proline-directed kinases and GSK-3beta/SGG in circadian clocks</span>. <span class="source" tagx="source" title="source">J Neurosci</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">30</span>:<span class="fpage" tagx="fpage" title="fpage">12664</span>â€"<span class="lpage" tagx="lpage" title="lpage">75</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20861372">20861372</a></span></span></li> <li tag="ref"><a name="CIT0074" /><span class="label" tagx="label" title="label">74</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leclerc</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Garnier</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoessel</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimerâ€™s disease. A property common to most cyclin-dependent kinase inhibitors?</span><span class="source" tagx="source" title="source">J Biol Chem</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">276</span>:<span class="fpage" tagx="fpage" title="fpage">251</span>â€"<span class="lpage" tagx="lpage" title="lpage">60</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11013232">11013232</a></span></span></li> <li tag="ref"><a name="CIT0075" /><span class="label" tagx="label" title="label">75</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bhat</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xue</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Berg</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</span>. <span class="source" tagx="source" title="source">J Biol Chem</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">278</span>:<span class="fpage" tagx="fpage" title="fpage">45937</span>â€"<span class="lpage" tagx="lpage" title="lpage">45</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12928438">12928438</a></span></span></li> <li tag="ref"><a name="CIT0076" /><span class="label" tagx="label" title="label">76</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vine</span><span class="given-names" tagx="given-names" title="given-names">KL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Matesic</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Locke</span><span class="given-names" tagx="given-names" title="given-names">JM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000â€"2008</span>. <span class="source" tagx="source" title="source">Anticancer Agents Med Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">397</span>â€"<span class="lpage" tagx="lpage" title="lpage">414</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19442041">19442041</a></span></span></li> <li tag="ref"><a name="CIT0077" /><span class="label" tagx="label" title="label">77</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">HA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keeton</span><span class="given-names" tagx="given-names" title="given-names">AB</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and inÂ vitro pharmacological profiling</span>. <span class="source" tagx="source" title="source">Drug Des Devel Ther</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">2333</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.</span></li> <li tag="ref"><a name="CIT0078" /><span class="label" tagx="label" title="label">78</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Warhi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aljaeed</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">2031</span>.</span></li> <li tag="ref"><a name="CIT0079" /><span class="label" tagx="label" title="label">79</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goodman</span><span class="given-names" tagx="given-names" title="given-names">VL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rock</span><span class="given-names" tagx="given-names" title="given-names">EP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dagher</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma</span>. <span class="source" tagx="source" title="source">Clin Cancer Res</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">1367</span>â€"<span class="lpage" tagx="lpage" title="lpage">73</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17332278">17332278</a></span></span></li> <li tag="ref"><a name="CIT0080" /><span class="label" tagx="label" title="label">80</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Inomata</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nishioka</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Azuma</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis</span>. <span class="source" tagx="source" title="source">Core Evid</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">89</span>â€"<span class="lpage" tagx="lpage" title="lpage">98</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26346347">26346347</a></span></span></li> <li tag="ref"><a name="CIT0081" /><span class="label" tagx="label" title="label">81</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jagtap</span><span class="given-names" tagx="given-names" title="given-names">AD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">PT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">JR</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">85</span>:<span class="fpage" tagx="fpage" title="fpage">268</span>â€"<span class="lpage" tagx="lpage" title="lpage">88</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25089810">25089810</a></span></span></li> <li tag="ref"><a name="CIT0082" /><span class="label" tagx="label" title="label">82</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yousefian</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghodsi</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents</span>. <span class="source" tagx="source" title="source">Arch Pharm (Weinheim)</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">353</span>:<span class="fpage" tagx="fpage" title="fpage">e2000022</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32885522">32885522</a></span></span></li> <li tag="ref"><a name="CIT0083" /><span class="label" tagx="label" title="label">83</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Kerdawy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Ansary</span><span class="given-names" tagx="given-names" title="given-names">GH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">163</span>:<span class="fpage" tagx="fpage" title="fpage">37</span>â€"<span class="lpage" tagx="lpage" title="lpage">53</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30503942">30503942</a></span></span></li> <li tag="ref"><a name="CIT0084" /><span class="label" tagx="label" title="label">84</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Laufer</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Forrest</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">SW</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">56</span>:<span class="fpage" tagx="fpage" title="fpage">6069</span>â€"<span class="lpage" tagx="lpage" title="lpage">87</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23829549">23829549</a></span></span></li> <li tag="ref"><a name="CIT0085" /><span class="label" tagx="label" title="label">85</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">HC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jagtap</span><span class="given-names" tagx="given-names" title="given-names">AD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">PT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">84</span>:<span class="fpage" tagx="fpage" title="fpage">312</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25036791">25036791</a></span></span></li> <li tag="ref"><a name="CIT0086" /><span class="label" tagx="label" title="label">86</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhong</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xue</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: molecular docking simulation and structure-activity relationship analysis</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">1724</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23434140">23434140</a></span></span></li> <li tag="ref"><a name="CIT0087" /><span class="label" tagx="label" title="label">87</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aneja</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">NS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">163</span>:<span class="fpage" tagx="fpage" title="fpage">840</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30579124">30579124</a></span></span></li> <li tag="ref"><a name="CIT0088" /><span class="label" tagx="label" title="label">88</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dweedar</span><span class="given-names" tagx="given-names" title="given-names">HE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahrous</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">HA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">78</span>:<span class="fpage" tagx="fpage" title="fpage">275</span>â€"<span class="lpage" tagx="lpage" title="lpage">80</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24686014">24686014</a></span></span></li> <li tag="ref"><a name="CIT0089" /><span class="label" tagx="label" title="label">89</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoessel</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leclerc</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Endicott</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases</span>. <span class="source" tagx="source" title="source">Nat Cell Biol</span><span class="year" tagx="year" title="year">1999</span>;<span class="volume" tagx="volume" title="volume">1</span>:<span class="fpage" tagx="fpage" title="fpage">60</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10559866">10559866</a></span></span></li> <li tag="ref"><a name="CIT0090" /><span class="label" tagx="label" title="label">90</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Damiens</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baratte</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marie</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest</span>. <span class="source" tagx="source" title="source">Oncogene</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">3786</span>â€"<span class="lpage" tagx="lpage" title="lpage">97</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11439342">11439342</a></span></span></li> <li tag="ref"><a name="CIT0091" /><span class="label" tagx="label" title="label">91</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marko</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schatzle</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Friedel</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells</span>. <span class="source" tagx="source" title="source">Br J Cancer</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">84</span>:<span class="fpage" tagx="fpage" title="fpage">283</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11161389">11161389</a></span></span></li> <li tag="ref"><a name="CIT0092" /><span class="label" tagx="label" title="label">92</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liang</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xia</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lei</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, inÂ vitro and inÂ vivo antitumor activity of symmetrical bis-Schiff base derivatives of isatin</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">74</span>:<span class="fpage" tagx="fpage" title="fpage">742</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24176732">24176732</a></span></span></li> <li tag="ref"><a name="CIT0093" /><span class="label" tagx="label" title="label">93</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meijer</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Skaltsounis</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Magiatis</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">GSK-3-selective inhibitors derived from Tyrian purple indirubins</span>. <span class="source" tagx="source" title="source">Chem Biol</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">1255</span>â€"<span class="lpage" tagx="lpage" title="lpage">66</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14700633">14700633</a></span></span></li> <li tag="ref"><a name="CIT0094" /><span class="label" tagx="label" title="label">94</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khanam</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shamsuzzaman</span><span class="given-names" tagx="given-names" title="given-names">Â </span></span></span>, <span class="mixed-article-title" title="mixed-article-title">Bioactive Benzofuran derivatives: a review</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">97</span>:<span class="fpage" tagx="fpage" title="fpage">483</span>â€"<span class="lpage" tagx="lpage" title="lpage">504</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25482554">25482554</a></span></span></li> <li tag="ref"><a name="CIT0095" /><span class="label" tagx="label" title="label">95</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Miao</span><span class="given-names" tagx="given-names" title="given-names">Y-h</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hu</span><span class="given-names" tagx="given-names" title="given-names">Y-h</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Natural source, bioactivity and synthesis of benzofuran derivatives</span>. <span class="source" tagx="source" title="source">RSC Adv</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">27510</span>â€"<span class="lpage" tagx="lpage" title="lpage">40</span>.</span></li> <li tag="ref"><a name="CIT0096" /><span class="label" tagx="label" title="label">96</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Georgey</span><span class="given-names" tagx="given-names" title="given-names">HH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">George</span><span class="given-names" tagx="given-names" title="given-names">RF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">ER.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Aurones and furoaurones: biological activities and synthesis</span>. <span class="source" tagx="source" title="source">Bull Faculty Pharm Cairo Univ</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">56</span>:<span class="fpage" tagx="fpage" title="fpage">121</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.</span></li> <li tag="ref"><a name="CIT0097" /><span class="label" tagx="label" title="label">97</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nocentini</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elsayed</span><span class="given-names" tagx="given-names" title="given-names">ZM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer</span>. <span class="source" tagx="source" title="source">ACS Med Chem Lett</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">1022</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32435420">32435420</a></span></span></li> <li tag="ref"><a name="CIT0098" /><span class="label" tagx="label" title="label">98</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xiang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hirth</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Asmussen</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">3050</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21507633">21507633</a></span></span></li> <li tag="ref"><a name="CIT0099" /><span class="label" tagx="label" title="label">99</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">SalomÃ©</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Narbonne</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ribeiro</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Benzofuran derivatives as a novel class of inhibitors of mTOR signaling</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">74</span>:<span class="fpage" tagx="fpage" title="fpage">41</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24445311">24445311</a></span></span></li> <li tag="ref"><a name="CIT0100" /><span class="label" tagx="label" title="label">100</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">SalomÃ©</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ribeiro</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chavagnan</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Benzofuran derivatives as anticancer inhibitors of mTOR signaling</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">81</span>:<span class="fpage" tagx="fpage" title="fpage">181</span>â€"<span class="lpage" tagx="lpage" title="lpage">91</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24836070">24836070</a></span></span></li> <li tag="ref"><a name="CIT0101" /><span class="label" tagx="label" title="label">101</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abd El-Karim</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anwar</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">63</span>:<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">12</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26368040">26368040</a></span></span></li> <li tag="ref"><a name="CIT0102" /><span class="label" tagx="label" title="label">102</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mosmann</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays</span>. <span class="source" tagx="source" title="source">J Immunol Methods</span><span class="year" tagx="year" title="year">1983</span>;<span class="volume" tagx="volume" title="volume">65</span>:<span class="fpage" tagx="fpage" title="fpage">55</span>â€"<span class="lpage" tagx="lpage" title="lpage">63</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6606682">6606682</a></span></span></li> <li tag="ref"><a name="CIT0103" /><span class="label" tagx="label" title="label">103</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cherukupalli</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chandrasekaran</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Krystof</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">79</span>:<span class="fpage" tagx="fpage" title="fpage">46</span>â€"<span class="lpage" tagx="lpage" title="lpage">59</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29753773">29753773</a></span></span></li> <li tag="ref"><a name="CIT0104" /><span class="label" tagx="label" title="label">104</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oakes</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Harrington</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle</span>. <span class="source" tagx="source" title="source">Cell Cycle</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">3302</span>â€"<span class="lpage" tagx="lpage" title="lpage">11</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25485510">25485510</a></span></span></li> <li tag="ref"><a name="CIT0105" /><span class="label" tagx="label" title="label">105</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martin</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Odajima</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hunt</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1)</span>. <span class="source" tagx="source" title="source">Cancer Cell</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">591</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15950907">15950907</a></span></span></li> <li tag="ref"><a name="CIT0106" /><span class="label" tagx="label" title="label">106</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Acikgoz</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guler</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Camlar</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure</span>. <span class="source" tagx="source" title="source">Spectrochim Acta A Mol Biomol Spectrosc</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">209</span>:<span class="fpage" tagx="fpage" title="fpage">150</span>â€"<span class="lpage" tagx="lpage" title="lpage">64</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30388586">30388586</a></span></span></li> <li tag="ref"><a name="CIT0107" /><span class="label" tagx="label" title="label">107</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rashid</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazur</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ji</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Analysis of the role of GSK3 in the mitotic checkpoint</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">14259</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30250048">30250048</a></span></span></li> <li tag="ref"><a name="CIT0108" /><span class="label" tagx="label" title="label">108</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gorczyca</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cytometric analyses to distinguish death processes</span>. <span class="source" tagx="source" title="source">Endocr Relat Cancer</span><span class="year" tagx="year" title="year">1999</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">17</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10732781">10732781</a></span></span></li> <li tag="ref"><a name="CIT0109" /><span class="label" tagx="label" title="label">109</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Davis</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benson</span><span class="given-names" tagx="given-names" title="given-names">BG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bramson</span><span class="given-names" tagx="given-names" title="given-names">HN</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors</span>. <span class="source" tagx="source" title="source">Science</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">291</span>:<span class="fpage" tagx="fpage" title="fpage">134</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11141566">11141566</a></span></span></li> <li tag="ref"><a name="CIT0110" /><span class="label" tagx="label" title="label">110</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bertrand</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thieffine</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vulpetti</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors</span>. <span class="source" tagx="source" title="source">J Mol Biol</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">333</span>:<span class="fpage" tagx="fpage" title="fpage">393</span>â€"<span class="lpage" tagx="lpage" title="lpage">407</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14529625">14529625</a></span></span></li> <li tag="ref"><a name="CIT0111" /><span class="label" tagx="label" title="label">111</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Attia</span><span class="given-names" tagx="given-names" title="given-names">MI</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Afifi</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres</span>. <span class="source" tagx="source" title="source">Plos One</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">e0181241</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28742842">28742842</a></span></span></li> <li tag="ref"><a name="CIT0112" /><span class="label" tagx="label" title="label">112</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abo-Ashour</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nocentini</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">157</span>:<span class="fpage" tagx="fpage" title="fpage">28</span>â€"<span class="lpage" tagx="lpage" title="lpage">36</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30071407">30071407</a></span></span></li> <li tag="ref"><a name="CIT0113" /><span class="label" tagx="label" title="label">113</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khanapure</span><span class="given-names" tagx="given-names" title="given-names">SP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">H-O</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Efficient synthesis of a benzo[b]furan building block</span>. <span class="source" tagx="source" title="source">Synth Commun</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">40</span>:<span class="fpage" tagx="fpage" title="fpage">3390</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.</span></li> <li tag="ref"><a name="CIT0114" /><span class="label" tagx="label" title="label">114</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abo-Ashour</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel [(3-indolylmethylene)hydrazono]indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and inÂ vitro biological evaluation</span>. <span class="source" tagx="source" title="source">J Enzyme Inhibit Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">33</span>:<span class="fpage" tagx="fpage" title="fpage">686</span>â€"<span class="lpage" tagx="lpage" title="lpage">700</span>.</span></li> <li tag="ref"><a name="CIT0115" /><span class="label" tagx="label" title="label">115</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sabt</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelhafez</span><span class="given-names" tagx="given-names" title="given-names">OM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Haggar</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, inÂ vitro biological evaluation, and QSAR studies</span>. <span class="source" tagx="source" title="source">J Enzyme Inhibit Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">33</span>:<span class="fpage" tagx="fpage" title="fpage">1095</span>â€"<span class="lpage" tagx="lpage" title="lpage">107</span>.</span></li> <li tag="ref"><a name="CIT0116" /><span class="label" tagx="label" title="label">116</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahdy</span><span class="given-names" tagx="given-names" title="given-names">HA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">MK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Metwaly</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, molecular modeling, inÂ vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">94</span>:<span class="fpage" tagx="fpage" title="fpage">103422</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31812261">31812261</a></span></span></li> <li tag="ref"><a name="CIT0117" /><span class="label" tagx="label" title="label">117</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Rashood</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and inÂ vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents</span>. <span class="source" tagx="source" title="source">J Enzyme Inhibit Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">322</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.</span></li> <li tag="ref"><a name="CIT0118" /><span class="label" tagx="label" title="label">118</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elmetwally</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saied</span><span class="given-names" tagx="given-names" title="given-names">KF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eissa</span><span class="given-names" tagx="given-names" title="given-names">IH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elkaeed</span><span class="given-names" tagx="given-names" title="given-names">EB.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers</span>. <span class="source" tagx="source" title="source">Bioorgan Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">88</span>:<span class="fpage" tagx="fpage" title="fpage">102944</span>.</span></li> <li tag="ref"><a name="CIT0119" /><span class="label" tagx="label" title="label">119</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sabt</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Warhi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights</span>. <span class="source" tagx="source" title="source">J Enzyme Inhibit Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">35</span>:<span class="fpage" tagx="fpage" title="fpage">1616</span>â€"<span class="lpage" tagx="lpage" title="lpage">30</span>.</span></li> <li tag="ref"><a name="CIT0120" /><span class="label" tagx="label" title="label">120</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Protein Data Bank. <a href="https://www.rcsb.org/">https://www.rcsb.org/</a> [last accessed10 Oct 2020].</span></li> </ul> </div> </div>  </body></html>